<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00242</drugbank-id>
  <drugbank-id>APRD00260</drugbank-id>
  <name>Cladribine</name>
  <description>An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.</description>
  <cas-number>4291-63-8</cas-number>
  <unii>47M74X9YT5</unii>
  <average-mass>285.687</average-mass>
  <monoisotopic-mass>285.062866982</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A349</ref-id>
        <pubmed-id>20689698</pubmed-id>
        <citation>Warnke C, Wiendl H, Hartung HP, Stuve O, Kieseier BC: Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther. 2010 Jul 21;4:117-26.</citation>
      </article>
      <article>
        <ref-id>A350</ref-id>
        <pubmed-id>20634380</pubmed-id>
        <citation>Sigal DS, Miller HJ, Schram ED, Saven A: Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010 Oct 21;116(16):2884-96. doi: 10.1182/blood-2010-02-246140. Epub 2010  Jul 15.</citation>
      </article>
      <article>
        <ref-id>A351</ref-id>
        <pubmed-id>1261088</pubmed-id>
        <citation>Khalid BA, Hamilton NT, Cauchi MN: Binding of thyroid microsomes by lymphocytes from patients with thyroid disease and normal subjects. Clin Exp Immunol. 1976 Jan;23(1):28-32.</citation>
      </article>
      <article>
        <ref-id>A352</ref-id>
        <pubmed-id>19715446</pubmed-id>
        <citation>Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.</citation>
      </article>
      <article>
        <ref-id>A353</ref-id>
        <pubmed-id>17852710</pubmed-id>
        <citation>Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.</citation>
      </article>
      <article>
        <ref-id>A354</ref-id>
        <pubmed-id>19576186</pubmed-id>
        <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
      </article>
      <article>
        <ref-id>A355</ref-id>
        <pubmed-id>19463072</pubmed-id>
        <citation>Larson ML, Venugopal P: Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jun;10(8):1353-7. doi: 10.1517/14656560902997990.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Szepsel Gerszberg, "Method for the production of 2-chloro-2&amp;apos; -deoxyadenosine (cladribine) and its 3,5-di-O-p-toluoyl derivative." U.S. Patent US20020052491, issued May 02, 2002.</synthesis-reference>
  <indication>For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.</indication>
  <pharmacodynamics>Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to enzymatic degradation by adenosine deaminase. Due to this resistance, cladribine exhibits a more prolonged cytotoxic effect than deoxyadenosine against resting and proliferating lymphocytes. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites.&amp;nbsp;Anti-metabolites stop cells from making and repairing DNA, which are processes that are necessary for cancer cells to grow and multiply.</pharmacodynamics>
  <mechanism-of-action>Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. Although the exact mechanism of action has not been fully determined, evidence shows that cladribine is phosphorylated by deoxycytidine kinase to the nucleotidecladribine triphosphate (CdATP; 2-chloro-2′-deoxyadenosine 5′-triphosphate), which accumulates and is incorporated into DNA in cells such as lymphocytes that contain high levels of deoxycytidine kinase and low levels of deoxynucleotidase, resulting in DNA strand breakage and inhibition of DNA synthesis and repair. High levels of CdATP also appear to inhibit ribonucleotide reductase, which leads to an imbalance in triphosphorylated deoxynucleotide (dNTP) pools and subsequent DNA strand breaks, inhibition of DNA synthesis and repair, nicotinamide adenine dinucleotide (NAD) and ATP depletion, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established.</mechanism-of-action>
  <toxicity>Symptoms of overdose include irreversible neurologic toxicity (paraparesis/quadriparesis), acute nephrotoxicity, and severe bone marrow suppression resulting in neutropenia, anemia and thrombocytopenia.</toxicity>
  <metabolism>Metabolized in all cells with deoxycytidine kinase activity to 2-chloro-2'-deoxyadenosine-5'-triphosphate</metabolism>
  <absorption>Oral bioavailability is 34 to 48%.</absorption>
  <half-life>5.4 hours</half-life>
  <protein-binding>20%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution>* 4.5 ± 2.8 L/kg [patients with hematologic malignancies]&#13;
* 9 L/kg</volume-of-distribution>
  <clearance>* 978 +/- 422 mL/h/kg</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as purine 2'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 2.</description>
    <direct-parent>Purine 2'-deoxyribonucleosides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Nucleosides, nucleotides, and analogues</superclass>
    <class>Purine nucleosides</class>
    <subclass>Purine 2'-deoxyribonucleosides</subclass>
    <alternative-parent>2-halopyrimidines</alternative-parent>
    <alternative-parent>6-aminopurines</alternative-parent>
    <alternative-parent>Aminopyrimidines and derivatives</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>N-substituted imidazoles</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Tetrahydrofurans</alternative-parent>
    <substituent>2-halopyrimidine</substituent>
    <substituent>6-aminopurine</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Amine</substituent>
    <substituent>Aminopyrimidine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Halopyrimidine</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Imidazopyrimidine</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>N-substituted imidazole</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Purine</substituent>
    <substituent>Purine 2'-deoxyribonucleoside</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tetrahydrofuran</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol</synonym>
    <synonym language="english" coder="">2-CdA</synonym>
    <synonym language="english" coder="">2-Chloro-2'-deoxy-beta-adenosine</synonym>
    <synonym language="english" coder="iupac">2-Chloro-2'-deoxyadenosine</synonym>
    <synonym language="english" coder="">2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine</synonym>
    <synonym language="english" coder="">2-chloro-deoxyadenosine</synonym>
    <synonym language="english" coder="">2-Chlorodeoxyadenosine</synonym>
    <synonym language="english" coder="">2ClAdo</synonym>
    <synonym language="spanish" coder="inn">Cladribina</synonym>
    <synonym language="english" coder="inn/usan">Cladribine</synonym>
    <synonym language="latin" coder="inn">Cladribinum</synonym>
    <synonym language="english" coder="">CldAdo</synonym>
  </synonyms>
  <products>
    <product>
      <name>Cladribine</name>
      <labeller>Onco Therapies Limited</labeller>
      <ndc-id/>
      <ndc-product-code>47351-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-07</started-marketing-on>
      <ended-marketing-on>2012-01-13</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA200510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-10</started-marketing-on>
      <ended-marketing-on>2018-04-17</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA200510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-07</started-marketing-on>
      <ended-marketing-on>2018-04-17</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA200510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Bedford Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55390-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-02-28</started-marketing-on>
      <ended-marketing-on>2012-12-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA075405</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Bedford Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55390-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-01</started-marketing-on>
      <ended-marketing-on>2012-12-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA075405</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>67457-451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-07</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA200510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>67457-450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA200510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Hikma Pharmaceuticals USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0143-9871</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA075405</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA076571</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cladribine Injection</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02319918</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Leustatin</name>
      <labeller>Janssen Products, L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>59676-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-03-01</started-marketing-on>
      <ended-marketing-on>2013-09-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020229</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leustatin 1mg/ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02022117</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2011-12-19</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mavenclad</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-6000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022561</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mavenclad</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-4000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022561</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mavenclad</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470179</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Litak</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Movectro</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Mylinax</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Leustatin</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Mavenclad</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Mavenclad</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Leustatin 1mg/ml</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Cladribine Injection</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
    <mixture>
      <name>Mavenclad</name>
      <ingredients>Cladribine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>APP Pharmaceuticals</name>
      <url>http://www.apppharma.com</url>
    </packager>
    <packager>
      <name>Bedford Labs</name>
      <url>http://www.bedfordlabs.com</url>
    </packager>
    <packager>
      <name>Ben Venue Laboratories Inc.</name>
      <url>http://www.benvenue.com</url>
    </packager>
    <packager>
      <name>Centocor Ortho Biotech Inc.</name>
      <url>http://www.centocororthobiotech.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="true" url="">App pharmaceuticals llc</manufacturer>
    <manufacturer generic="true" url="">Bedford laboratories div ben venue laboratories inc</manufacturer>
    <manufacturer generic="false" url="">Ortho biotech products lp</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Cladribine 10 mg/10 ml vial</description>
      <cost currency="USD">34.2</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Leustatin 10 mg/10 ml vial</description>
      <cost currency="USD">102.78</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>2-Chloroadenosine</category>
      <mesh-id>D015762</mesh-id>
    </category>
    <category>
      <category>Agents Causing Muscle Toxicity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antimetabolites</category>
      <mesh-id>D000963</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>BCRP/ABCG2 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Cardiotoxic antineoplastic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Deoxyadenosines</category>
      <mesh-id>D003839</mesh-id>
    </category>
    <category>
      <category>Deoxyribonucleosides</category>
      <mesh-id>D003853</mesh-id>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Myelosuppressive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nucleic Acids, Nucleotides, and Nucleosides</category>
      <mesh-id>D009706</mesh-id>
    </category>
    <category>
      <category>Nucleosides</category>
      <mesh-id>D009705</mesh-id>
    </category>
    <category>
      <category>Purine Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Purine Antimetabolite</category>
      <mesh-id/>
    </category>
    <category>
      <category>Purine Nucleosides</category>
      <mesh-id>D011684</mesh-id>
    </category>
    <category>
      <category>Purines</category>
      <mesh-id>D011687</mesh-id>
    </category>
    <category>
      <category>Ribonucleosides</category>
      <mesh-id>D012263</mesh-id>
    </category>
    <category>
      <category>Selective Immunosuppressants</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L04AA40">
      <level code="L04AA">Selective immunosuppressants</level>
      <level code="L04A">IMMUNOSUPPRESSANTS</level>
      <level code="L04">IMMUNOSUPPRESSANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
    <atc-code code="L01BB04">
      <level code="L01BB">Purine analogues</level>
      <level code="L01B">ANTIMETABOLITES</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
    <ahfs-code>92:44.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2zi9</pdb-entry>
    <pdb-entry>2zia</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00242.pdf?1265922741</msds>
  <patents>
    <patent>
      <number>7888328</number>
      <country>United States</country>
      <approved>2011-02-15</approved>
      <expires>2024-04-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8785415</number>
      <country>United States</country>
      <approved>2014-07-22</approved>
      <expires>2024-04-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7713947</number>
      <country>United States</country>
      <approved>2010-05-11</approved>
      <expires>2026-10-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8377903</number>
      <country>United States</country>
      <approved>2013-02-19</approved>
      <expires>2026-05-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use. </food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may increase the immunosuppressive activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06688</drugbank-id>
      <name>Sipuleucel-T</name>
      <description>The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of neutropenia can be increased when Cladribine is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of myelosuppression can be increased when Metamizole is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>Cladribine may increase the immunosuppressive activities of Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Cladribine may increase the immunosuppressive activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may increase the immunosuppressive activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Oleandrin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>Cymarin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>Proscillaridin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>Metildigoxin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>Lanatoside C may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>Gitoformate may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>Acetyldigoxin may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>Peruvoside may decrease the cardiotoxic activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Anastrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06013</drugbank-id>
      <name>Aldoxorubicin</name>
      <description>The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Aldoxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06171</drugbank-id>
      <name>Paclitaxel trevatide</name>
      <description>The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Paclitaxel trevatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13809</drugbank-id>
      <name>Paclitaxel poliglumex</name>
      <description>The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Paclitaxel poliglumex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05144</drugbank-id>
      <name>PEV3A</name>
      <description>The therapeutic efficacy of PEV3A can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06400</drugbank-id>
      <name>Vitespen</name>
      <description>The therapeutic efficacy of Vitespen can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10062</drugbank-id>
      <name>Rabies virus inactivated antigen, B</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10076</drugbank-id>
      <name>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10276</drugbank-id>
      <name>Rotavirus vaccine</name>
      <description>The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10342</drugbank-id>
      <name>Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10583</drugbank-id>
      <name>Clostridium tetani toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10584</drugbank-id>
      <name>Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10600</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10769</drugbank-id>
      <name>Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10794</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10803</drugbank-id>
      <name>Typhoid Vi polysaccharide vaccine</name>
      <description>The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10989</drugbank-id>
      <name>Hepatitis A Vaccine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10990</drugbank-id>
      <name>Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11038</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11040</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11041</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11044</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11603</drugbank-id>
      <name>Human rabies virus immune globulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11627</drugbank-id>
      <name>Hepatitis B Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12568</drugbank-id>
      <name>Tecemotide</name>
      <description>The therapeutic efficacy of Tecemotide can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14384</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14385</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14394</drugbank-id>
      <name>Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14445</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14449</drugbank-id>
      <name>Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14619</drugbank-id>
      <name>Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14620</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14711</drugbank-id>
      <name>Vaccinia virus strain new york city board of health live antigen</name>
      <description>The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15274</drugbank-id>
      <name>Pertussis vaccine</name>
      <description>The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15461</drugbank-id>
      <name>Yersinia pestis 195/p antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13924</drugbank-id>
      <name>Varicella Zoster Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15483</drugbank-id>
      <name>Modified vaccinia ankara</name>
      <description>The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of bleeding can be increased when Abciximab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>The risk or severity of bleeding can be increased when Eptifibatide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The risk or severity of bleeding can be increased when Ticlopidine is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of bleeding can be increased when Anagrelide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The risk or severity of bleeding can be increased when Clopidogrel is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>The risk or severity of bleeding can be increased when Tirofiban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of bleeding can be increased when Pentoxifylline is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of bleeding can be increased when Dipyridamole is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of bleeding can be increased when Cilostazol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>The risk or severity of bleeding can be increased when Ridogrel is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of bleeding can be increased when Sevoflurane is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of bleeding can be increased when Epoprostenol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of bleeding can be increased when Resveratrol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of bleeding can be increased when Nimesulide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The risk or severity of bleeding can be increased when Tesmilifene is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The risk or severity of bleeding can be increased when Defibrotide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The risk or severity of bleeding can be increased when Beraprost is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of bleeding can be increased when Ibudilast is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of bleeding can be increased when Andrographolide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of bleeding can be increased when Caplacizumab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The risk or severity of bleeding can be increased when Prasugrel is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The risk or severity of bleeding can be increased when Cangrelor is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of bleeding can be increased when Tranilast is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The risk or severity of bleeding can be increased when Triflusal is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The risk or severity of bleeding can be increased when Ticagrelor is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of bleeding can be increased when Vorapaxar is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>The risk or severity of bleeding can be increased when Trapidil is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of bleeding can be increased when Naftopidil is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of bleeding can be increased when Sarpogrelate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>The risk or severity of bleeding can be increased when Ifetroban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of bleeding can be increased when Nitroaspirin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of bleeding can be increased when Ketanserin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of bleeding can be increased when Indobufen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>The risk or severity of bleeding can be increased when Butylphthalide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>The risk or severity of bleeding can be increased when Ramatroban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>The risk or severity of bleeding can be increased when Picotamide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>The risk or severity of bleeding can be increased when Cloricromen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of bleeding can be increased when Linsidomine is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of bleeding can be increased when Buflomedil is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>The risk or severity of bleeding can be increased when Relcovaptan is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>Ocrelizumab may increase the immunosuppressive activities of Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>Cladribine may increase the myelosuppressive activities of Lipegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The risk or severity of infection can be increased when Anthrax vaccine is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The risk or severity of infection can be increased when BCG vaccine is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00039</drugbank-id>
      <name>Palifermin</name>
      <description>The therapeutic efficacy of Palifermin can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00052</drugbank-id>
      <name>Somatotropin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Pamidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Mefloquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Tacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Carbimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Cerivastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Montelukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Nizatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ivermectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Niacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Simvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Stavudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00666</drugbank-id>
      <name>Nafarelin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Nafarelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Amphotericin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Naltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Lamivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Eprosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Risedronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Triazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Salmeterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Methyldopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Isotretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ganciclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Letrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06693</drugbank-id>
      <name>Mevastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Mevastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06817</drugbank-id>
      <name>Raltegravir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Raltegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Pitavastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08983</drugbank-id>
      <name>Etofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Etofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09055</drugbank-id>
      <name>Acipimox</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Acipimox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09064</drugbank-id>
      <name>Ciprofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ciprofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ubidecarenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ipecac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13393</drugbank-id>
      <name>Emetine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Emetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13433</drugbank-id>
      <name>Simfibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Simfibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13460</drugbank-id>
      <name>Ronifibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ronifibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13780</drugbank-id>
      <name>Aluminium clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Aluminium clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13849</drugbank-id>
      <name>Clofibride</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Clofibride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Fenofibric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The risk or severity of bleeding can be increased when Bivalirudin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of bleeding can be increased when Alteplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The risk or severity of bleeding can be increased when Urokinase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of bleeding can be increased when Reteplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of bleeding can be increased when Anistreplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of bleeding can be increased when Tenecteplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of bleeding can be increased when Streptokinase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Dicoumarol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The risk or severity of bleeding can be increased when Argatroban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of bleeding can be increased when Ardeparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Phenindione is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The risk or severity of bleeding can be increased when Fondaparinux is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Warfarin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Phenprocoumon is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of bleeding can be increased when Heparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of bleeding can be increased when Enoxaparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Coumarin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The risk or severity of bleeding can be increased when Ximelagatran is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The risk or severity of bleeding can be increased when Desmoteplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The risk or severity of bleeding can be increased when Ancrod is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The risk or severity of bleeding can be increased when Fibrinolysin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The risk or severity of bleeding can be increased when Rivaroxaban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of bleeding can be increased when Sulodexide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of bleeding can be increased when Semuloparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The risk or severity of bleeding can be increased when Idraparinux is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The risk or severity of bleeding can be increased when Astaxanthin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The risk or severity of bleeding can be increased when Apixaban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The risk or severity of bleeding can be increased when Otamixaban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of bleeding can be increased when Amediplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of bleeding can be increased when Danaparoid is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of bleeding can be increased when Dalteparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of bleeding can be increased when Tinzaparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of bleeding can be increased when Ferulic acid is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when (R)-warfarin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of bleeding can be increased when Nadroparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The risk or severity of bleeding can be increased when Ditazole is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The risk or severity of bleeding can be increased when Edoxaban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of bleeding can be increased when Potassium citrate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The risk or severity of bleeding can be increased when Dextran is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of bleeding can be increased when Bemiparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of bleeding can be increased when Reviparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of bleeding can be increased when Parnaparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of bleeding can be increased when Certoparin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The risk or severity of bleeding can be increased when Desirudin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The risk or severity of bleeding can be increased when Zinc citrate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The risk or severity of bleeding can be increased when Protein C is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The risk or severity of bleeding can be increased when Antithrombin III human is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The risk or severity of bleeding can be increased when Letaxaban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The risk or severity of bleeding can be increased when Darexaban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The risk or severity of bleeding can be increased when Betrixaban is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of bleeding can be increased when Nafamostat is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The risk or severity of bleeding can be increased when Monteplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The risk or severity of bleeding can be increased when Gabexate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Fluindione is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The risk or severity of bleeding can be increased when Protein S human is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The risk or severity of bleeding can be increased when Brinase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Clorindione is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Diphenadione is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Tioclomarol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The risk or severity of bleeding can be increased when Melagatran is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of bleeding can be increased when Saruplase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Edetate disodium anhydrous is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Diazoxide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cladribine may increase the immunosuppressive activities of Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>The risk or severity of adverse effects can be increased when Allopurinol is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Adalimumab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of adverse effects can be increased when Infliximab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Rituximab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Basiliximab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The risk or severity of adverse effects can be increased when Muromonab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Tositumomab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00092</drugbank-id>
      <name>Alefacept</name>
      <description>The risk or severity of adverse effects can be increased when Alefacept is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Efalizumab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Daclizumab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of adverse effects can be increased when Flunisolide is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of adverse effects can be increased when Bortezomib is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Bleomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dexrazoxane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Linezolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Azathioprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mycophenolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01423</drugbank-id>
      <name>Stepronin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Stepronin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Castanospermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02806</drugbank-id>
      <name>2-Methoxyethanol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with 2-Methoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05259</drugbank-id>
      <name>Glatiramer</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Glatiramer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>omega interferon</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with omega interferon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06662</drugbank-id>
      <name>Abetimus</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Abetimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06681</drugbank-id>
      <name>Belatacept</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Belatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08908</drugbank-id>
      <name>Dimethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dimethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11693</drugbank-id>
      <name>Voclosporin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Voclosporin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11708</drugbank-id>
      <name>Peficitinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Peficitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12612</drugbank-id>
      <name>Ozanimod</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Ozanimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13068</drugbank-id>
      <name>9-(N-methyl-L-isoleucine)-cyclosporin A</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13241</drugbank-id>
      <name>Begelomab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Begelomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14219</drugbank-id>
      <name>Monomethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Monomethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the excretion rate of Cladribine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04540</drugbank-id>
      <name>Cholesterol</name>
      <description>Cholesterol may increase the excretion rate of Cladribine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>Apalutamide may increase the excretion rate of Cladribine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Cladribine can be increased when it is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>The serum concentration of Cladribine can be increased when it is combined with Darolutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>The risk or severity of cytotoxicity can be increased when Ancestim is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Pravastatin may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>Pantoprazole may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>Nelfinavir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>Gefitinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>Omeprazole may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>Lansoprazole may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>Ritonavir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>Erlotinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Buprenorphine may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Telmisartan may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>Ezetimibe may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01051</drugbank-id>
      <name>Novobiocin</name>
      <description>Novobiocin may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>Hesperetin may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Rabeprazole may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>Saquinavir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>Genistein may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Topiroxostat may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02115</drugbank-id>
      <name>Daidzin</name>
      <description>Daidzin may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>Fusidic acid may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03467</drugbank-id>
      <name>Naringenin</name>
      <description>Naringenin may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>Quercetin may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>Taurocholic acid may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>Elacridar may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>Vandetanib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>Dovitinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>Eltrombopag may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>Simeprevir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>Vismodegib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>Rilpivirine may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>Vemurafenib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>Regorafenib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>Dabrafenib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>Afatinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>Cannabidiol may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>Cobicistat may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>Daclatasvir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>Dasabuvir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>Rolapitant may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>Paritaprevir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>Alectinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>Venetoclax may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>Velpatasvir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>Isavuconazole may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>Dacomitinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>Glasdegib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>Avatrombopag may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>Abemaciclib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>Fostamatinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>Voxilaprevir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>Letermovir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>Gilteritinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>Brigatinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>Rucaparib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>Enasidenib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>Pibrentasvir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>Glecaprevir may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>Estradiol dienanthate may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>Medical Cannabis may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>Nabiximols may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>Fedratinib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>Istradefylline may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>Caffeine may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.12</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.35e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.28</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>cladribine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>285.687</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>285.062866982</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C10H12ClN5O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>PTOAARAWEBMLNO-KVQBGUIXSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>119.31</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>67.18</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>25.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>1.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>215 °C</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.1</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1739</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>567361</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>20279</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504588</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01370</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>19105</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>38920</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449027</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>CL9</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000565</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cladribine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1619</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/cladribine.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/cladribine.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00242</drugbank-id>
        <name>Cladribine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00677</drugbank-id>
        <name>2-chloro-2'-deoxyadenosine-5'-triphosphate</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000325</id>
      <name>Ribonucleoside-diphosphate reductase large subunit</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A352</ref-id>
            <pubmed-id>19715446</pubmed-id>
            <citation>Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.</citation>
          </article>
          <article>
            <ref-id>A353</ref-id>
            <pubmed-id>17852710</pubmed-id>
            <citation>Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.</citation>
          </article>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
          <article>
            <ref-id>A6595</ref-id>
            <pubmed-id>16316309</pubmed-id>
            <citation>Kline JP, Larson RA: Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005 Dec;6(15):2711-8.</citation>
          </article>
          <article>
            <ref-id>A15624</ref-id>
            <pubmed-id>9923554</pubmed-id>
            <citation>Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M: Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol. 1999;43(3):233-40.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P23921" source="Swiss-Prot">
        <name>Ribonucleoside-diphosphate reductase large subunit</name>
        <general-function>Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor</general-function>
        <specific-function>Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.</specific-function>
        <gene-name>RRM1</gene-name>
        <locus>11p15.5</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.16</theoretical-pi>
        <molecular-weight>90069.375</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10451</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RRM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X59543</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>36065</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2630</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P23921</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RIR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.17.4.1</synonym>
          <synonym>Ribonucleoside-diphosphate reductase subunit M1</synonym>
          <synonym>Ribonucleotide reductase large subunit</synonym>
          <synonym>RR1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010086|Ribonucleoside-diphosphate reductase large subunit
MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSGVTTVELDTLA
AETAATLTTKHPDYAILAARIAVSNLHKETKKVFSDVMEDLYNYINPHNGKHSPMVAKST
LDIVLANKDRLNSAIIYDRDFSYNYFGFKTLERSYLLKINGKVAERPQHMLMRVSVGIHK
EDIDAAIETYNLLSERWFTHASPTLFNAGTNRPQLSSCFLLSMKDDSIEGIYDTLKQCAL
ISKSAGGIGVAVSCIRATGSYIAGTNGNSNGLVPMLRVYNNTARYVDQGGNKRPGAFAIY
LEPWHLDIFEFLDLKKNTGKEEQRARDLFFALWIPDLFMKRVETNQDWSLMCPNECPGLD
EVWGEEFEKLYASYEKQGRVRKVVKAQQLWYAIIESQTETGTPYMLYKDSCNRKSNQQNL
GTIKCSNLCTEIVEYTSKDEVAVCNLASLALNMYVTSEHTYDFKKLAEVTKVVVRNLNKI
IDINYYPVPEACLSNKRHRPIGIGVQGLADAFILMRYPFESAEAQLLNKQIFETIYYGAL
EASCDLAKEQGPYETYEGSPVSKGILQYDMWNVTPTDLWDWKVLKEKIAKYGIRNSLLIA
PMPTASTAQILGNNESIEPYTSNIYTRRVLSGEFQIVNPHLLKDLTERGLWHEEMKNQII
ACNGSIQSIPEIPDDLKQLYKTVWEISQKTVLKMAAERGAFIDQSQSLNIHIAEPNYGKL
TSMHFYGWKQGLKTGMYYLRTRPAANPIQFTLNKEKLKDKEKVSKEEEEKERNTAAMVCS
LENRDECLMCGS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010087|Ribonucleoside-diphosphate reductase large subunit (RRM1)
ATGCATGTGATCAAGCGAGATGGCCGCCAAGAACGAGTCATGTTTGACAAAATTACATCT
CGAATCCAGAAGCTTTGTTATGGACTCAATATGGATTTTGTTGATCCTGCTCAGATCACC
ATGAAAGTAATCCAAGGCTTGTACAGTGGGGTCACCACAGTGGAACTAGATACTTTGGCT
GCTGAAACAGCTGCAACCTTGACTACTAAGCACCCTGACTATGCTATCCTGGCAGCCAGG
ATCGCTGTCTCTAACTTGCACAAAGAAACAAAGAAAGTGTTCAGTGATGTGATGGAAGAC
CTCTATAACTACATAAATCCACATAATGGCAAACACTCTCCCATGGTGGCCAAGTCAACA
TTGGATATTGTTCTGGCCAATAAAGATCGCCTGAATTCTGCTATTATCTATGACCGAGAT
TTCTCTTACAATTACTTCGGCTTTAAGACGCTAGAGCGGTCTTATTTGTTGAAGATCAAT
GGAAAAGTGGCTGAAAGACCACAACATATGTTGATGAGAGTATCTGTTGGGATCCACAAA
GAAGACATTGATGCAGCAATTGAAACATATAATCTTCTTTCTGAGAGGTGGTTTACTCAT
GCTTCGCCCACTCTCTTCAATGCTGGTACCAACCGCCCACAACTTTCTAGCTGTTTTCTT
CTGAGTATGAAAGATGACAGCATTGAAGGCATTTATGACACTCTAAAGCAATGTGCATTG
ATTTCTAAGTCTGCTGGAGGAATTGGTGTTGCTGTGAGTTGTATTCGGGCTACTGGCAGC
TACATTGCTGGGACTAATGGCAATTCCAATGGCCTTGTACCGATGCTGAGAGTATATAAC
AACACAGCTCGATATGTGGATCAAGGTGGGAACAAGCGTCCTGGGGCATTTGCTATTTAC
CTGGAGCCTTGGCATTTAGACATCTTTGAATTCCTTGATTTAAAGAAGAACACAGGAAAG
GAAGAGCAGCGTGCCAGAGATCTTTTCTTTGCTCTTTGGATTCCGGATCTCTTCATGAAA
CGAGTGGAGACTAATCAGGACTGGTCTTTGATGTGTCCAAATGAGTGTCCTGGTCTGGAT
GAGGTTTGGGGAGAGGAATTTGAGAAACTATATGCAAGTTATGAGAAACAAGGTCGTGTC
CGCAAAGTTGTAAAAGCTCAGCAGCTTTGGTATGCCATCATTGAGTCTCAGACGGAAACA
GGCACCCCGTATATGCTCTACAAAGATTCCTGTAATCGAAAGAGCAACCAGCAGAACCTG
GGAACCATCAAATGCAGCAACCTGTGCACAGAAATAGTGGAGTACACCAGCAAAGATGAG
GTTGCTGTTTGTAATTTGGCTTCCCTGGCCCTGAATATGTATGTCACATCAGAACACACA
TACGACTTTAAGAAGTTGGCTGAAGTCACTAAAGTCGTTGTCCGAAACTTGAATAAAATT
ATTGATATAAACTACTATCCTGTACCAGAGGCATGCCTATCAAATAAACGCCATCGCCCC
ATTGGAATTGGGGTACAAGGTCTGGCAGATGCTTTTATCCTGATGAGATACCCTTTTGAG
AGTGCAGAAGCCCAGTTACTGAATAAGCAGATCTTTGAAACTATTTATTATGGTGCTCTG
GAAGCCAGCTGTGACCTTGCCAAGGAGCAGGGCCCATACGAAACCTATGAGGGCTCTCCA
GTTAGCAAAGGAATTCTTCAGTATGATATGTGGAATGTTACTCCTACAGACCTATGGGAC
TGGAAGGTTCTCAAGGAGAAGATTGCAAAGTATGGTATAAGAAACAGTTTACTTATTGCC
CCGATGCCTACAGCTTCCACTGCTCAGATCCTGGGGAATAATGAGTCCATTGAACCTTAC
ACCAGCAACATCTATACTCGCAGAGTCTTGTCAGGAGAATTTCAGATTGTAAATCCTCAC
TTATTGAAAGATCTTACCGAGCGGGGCCTATGGCATGAAGAGATGAAAAACCAGATTATT
GCATGCAATGGCTCTATTCAGAGCATACCAGAAATTCCTGATGACCTGAAGCAACTTTAT
AAAACTGTGTGGGAAATCTCTCAGAAAACTGTTCTCAAGATGGCAGCTGAGAGAGGTGCT
TTCATTGATCAAAGCCAATCTTTGAACATCCACATTGCTGAGCCTAACTATGGCAAACTC
ACTAGTATGCACTTCTACGGCTGGAAGCAGGGTTTGAAGACTGGGATGTATTATTTAAGG
ACAAGACCAGCGGCTAATCCAATCCAGTTCACTCTAAATAAGGAGAAGCTAAAAGATAAA
GAAAAGGTATCAAAAGAGGAAGAAGAGAAGGAGAGGAACACAGCAGCCATGGTGTGCTCT
TTGGAGAATAGAGATGAATGTCTGATGTGTGGATCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03477</identifier>
            <name>ATP-cone</name>
          </pfam>
          <pfam>
            <identifier>PF02867</identifier>
            <name>Ribonuc_red_lgC</name>
          </pfam>
          <pfam>
            <identifier>PF00317</identifier>
            <name>Ribonuc_red_lgN</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ribonucleoside-diphosphate reductase complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation in forebrain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleotide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule interconversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ionizing radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0002450</id>
      <name>Ribonucleoside-diphosphate reductase subunit M2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A352</ref-id>
            <pubmed-id>19715446</pubmed-id>
            <citation>Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.</citation>
          </article>
          <article>
            <ref-id>A353</ref-id>
            <pubmed-id>17852710</pubmed-id>
            <citation>Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.</citation>
          </article>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
          <article>
            <ref-id>A6595</ref-id>
            <pubmed-id>16316309</pubmed-id>
            <citation>Kline JP, Larson RA: Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005 Dec;6(15):2711-8.</citation>
          </article>
          <article>
            <ref-id>A15624</ref-id>
            <pubmed-id>9923554</pubmed-id>
            <citation>Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M: Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol. 1999;43(3):233-40.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P31350" source="Swiss-Prot">
        <name>Ribonucleoside-diphosphate reductase subunit M2</name>
        <general-function>Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor</general-function>
        <specific-function>Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signaling.</specific-function>
        <gene-name>RRM2</gene-name>
        <locus>2p25-p24</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.05</theoretical-pi>
        <molecular-weight>44877.25</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10452</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RRM2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X59618</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31350</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RIR2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.17.4.1</synonym>
          <synonym>Ribonucleotide reductase small chain</synonym>
          <synonym>Ribonucleotide reductase small subunit</synonym>
          <synonym>RR2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004811|Ribonucleoside-diphosphate reductase subunit M2
MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARRIFQEPTEPKT
KAAAPGVEDEPLLRENPRRFVIFPIEYHDIWQMYKKAEASFWTAEEVDLSKDIQHWESLK
PEERYFISHVLAFFAASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLI
DTYIKDPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEGIFFSGSF
ASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHKPSEERVREIIINAVRIE
QEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLELGFSKVFRVENPFDFMENISLEGKTN
FFEKRVGEYQRMGVMSSPTENSFTLDADF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019288|Ribonucleoside-diphosphate reductase subunit M2 (RRM2)
ATGCTCTCCCTCCGTGTCCCGCTCGCGCCCATCACGGACCCGCAGCAGCTGCAGCTCTCG
CCGCTGAAGGGGCTCAGCTTGGTCGACAAGGAGAACACGCCGCCGGCCCTGAGCGGGACC
CGCGTCCTGGCCAGCAAGACCGCGAGGAGGATCTTCCAGGAGCCCACGGAGCCGAAAACT
AAAGCAGCTGCCCCCGGCGTGGAGGATGAGCCGCTGCTGAGAGAAAACCCCCGCCGCTTT
GTCATCTTCCCCATCGAGTACCATGATATCTGGCAGATGTATAAGAAGGCAGAGGCTTCC
TTTTGGACCGCCGAGGAGGTGGACCTCTCCAAGGACATTCAGCACTGGGAATCCCTGAAA
CCCGAGGAGAGATATTTTATATCCCATGTTCTGGCTTTCTTTGCAGCAAGCGATGGCATA
GTAAATGAAAACTTGGTGGAGCGATTTAGCCAAGAAGTTCAGATTACAGAAGCCCGCTGT
TTCTATGGCTTCCAAATTGCCATGGAAAACATACATTCTGAAATGTATAGTCTTCTTATT
GACACTTACATAAAAGATCCCAAAGAAAGGGAATTTCTCTTCAATGCCATTGAAACGATG
CCTTGTGTCAAGAAGAAGGCAGACTGGGCCTTGCGCTGGATTGGGGACAAAGAGGCTACC
TATGGTGAACGTGTTGTAGCCTTTGCTGCAGTGGAAGGCATTTTCTTTTCCGGTTCTTTT
GCGTCGATATTCTGGCTCAAGAAACGAGGACTGATGCCTGGCCTCACATTTTCTAATGAA
CTTATTAGCAGAGATGAGGGTTTACACTGTGATTTTGCTTGCCTGATGTTCAAACACCTG
GTACACAAACCATCGGAGGAGAGAGTAAGAGAAATAATTATCAATGCTGTTCGGATAGAA
CAGGAGTTCCTCACTGAGGCCTTGCCTGTGAAGCTCATTGGGATGAATTGCACTCTAATG
AAGCAATACATTGAGTTTGTGGCAGACAGACTTATGCTGGAACTGGGTTTTAGCAAGGTT
TTCAGAGTAGAGAACCCATTTGACTTTATGGAGAATATTTCACTGGAAGGAAAGACTAAC
TTCTTTGAGAAGAGAGTAGGCGAGTATCAGAGGATGGGAGTGATGTCAAGTCCAACAGAG
AATTCTTTTACCTTGGATGCTGACTTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00268</identifier>
            <name>Ribonuc_red_sm</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ribonucleoside-diphosphate reductase complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleoside diphosphate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleotide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule interconversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0003613</id>
      <name>Ribonucleoside-diphosphate reductase subunit M2 B</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A352</ref-id>
            <pubmed-id>19715446</pubmed-id>
            <citation>Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.</citation>
          </article>
          <article>
            <ref-id>A353</ref-id>
            <pubmed-id>17852710</pubmed-id>
            <citation>Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.</citation>
          </article>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
          <article>
            <ref-id>A6595</ref-id>
            <pubmed-id>16316309</pubmed-id>
            <citation>Kline JP, Larson RA: Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005 Dec;6(15):2711-8.</citation>
          </article>
          <article>
            <ref-id>A15624</ref-id>
            <pubmed-id>9923554</pubmed-id>
            <citation>Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M: Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol. 1999;43(3):233-40.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q7LG56" source="Swiss-Prot">
        <name>Ribonucleoside-diphosphate reductase subunit M2 B</name>
        <general-function>Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor</general-function>
        <specific-function>Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage.</specific-function>
        <gene-name>RRM2B</gene-name>
        <locus>8q23.1</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.61</theoretical-pi>
        <molecular-weight>40736.11</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:17296</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB036063</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7229086</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q7LG56</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RIR2B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.17.4.1</synonym>
          <synonym>p53-inducible ribonucleotide reductase small subunit 2-like protein</synonym>
          <synonym>P53R2</synonym>
          <synonym>TP53-inducible ribonucleotide reductase M2 B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006951|Ribonucleoside-diphosphate reductase subunit M2 B
MGDPERPEAAGLDQDERSSSDTNESEIKSNEEPLLRKSSRRFVIFPIQYPDIWKMYKQAQ
ASFWTAEEVDLSKDLPHWNKLKADEKYFISHILAFFAASDGIVNENLVERFSQEVQVPEA
RCFYGFQILIENVHSEMYSLLIDTYIRDPKKREFLFNAIETMPYVKKKADWALRWIADRK
STFGERVVAFAAVEGVFFSGSFAAIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFQ
YLVNKPSEERVREIIVDAVKIEQEFLTEALPVGLIGMNCILMKQYIEFVADRLLVELGFS
KVFQAENPFDFMENISLEGKTNFFEKRVSEYQRFAVMAETTDNVFTLDADF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021362|Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)
ATGTTGCTGTTGCGTCTTCCCCCTCACCGCAGTCACGCCAGCCCGTTAGATTGCAAGTTG
CAGGACCGCTGTAGGAAATGTTATTCGCCGCGGTCAGGACAGGCCTGTCCGCCCGCCCTC
GCCGCAGCCTGGCTTCGTCGTTGCGAGCGCCGGGGAGGCCGTCCCCGGGGAGGGCGGAGG
AAGGAGCTGACTTTGGGTTTGCGTCCCGCTCGCTGCTCTGCCCCGGGGCCAGCCAAGGAC
GACGCTTGGAGGCCTCAGGCCGGGAGATCATCTTCAGACACCAACGAAAGTGAAATAAAG
TCAAATGAAGAGCCACTCCTAAGAAAGAGTTCTCGCCGGTTTGTCATCTTTCCAATCCAG
TACCCTGATATTTGGAAAATGTATAAACAGGCACAGGCTTCCTTCTGGACAGCAGAAGAG
GTCGACTTATCAAAGGATCTCCCTCACTGGAACAAGCTTAAAGCAGATGAGAAGTACTTC
ATCTCTCACATCTTAGCCTTTTTTGCAGCCAGTGATGGAATTGTAAATGAAAATTTGGTG
GAGCGCTTTAGTCAGGAGGTGCAGGTTCCAGAGGCTCGCTGTTTCTATGGCTTTCAAATT
CTCATCGAGAATGTTCACTCAGAGATGTACAGTTTGCTGATAGACACTTACATCAGAGAT
CCCAAGAAAAGGGAATTTTTATTTAATGCAATTGAAACCATGCCCTATGTTAAGAAAAAA
GCAGATTGGGCCTTGCGATGGATAGCAGATAGAAAATCTACTTTTGGGGAAAGAGTGGTG
GCCTTTGCTGCTGTAGAAGGAGTTTTCTTCTCAGGATCTTTTGCTGCTATATTCTGGCTA
AAGAAGAGAGGTCTTATGCCAGGACTCACTTTTTCCAATGAACTCATCAGCAGAGATGAA
GGACTTCACTGTGACTTTGCTTGCCTGATGTTCCAATACTTAGTAAATAAGCCTTCAGAA
GAAAGGGTCAGGGAGATCATTGTTGATGCTGTCAAAATTGAGCAGGAGTTTTTAACAGAA
GCCTTGCCAGTTGGCCTCATTGGAATGAATTGCATTTTGATGAAACAGTACATTGAGTTT
GTAGCTGACAGATTACTTGTGGAACTTGGATTCTCAAAGGTTTTTCAGGCAGAAAATCCT
TTTGATTTTATGGAAAACATTTCTTTAGAAGGAAAAACAAATTTCTTTGAGAAACGAGTT
TCAGAGTATCAGCGTTTTGCAGTTATGGCAGAAACCACAGATAACGTCTTCACCTTGGAT
GCAGATTTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00268</identifier>
            <name>Ribonuc_red_sm</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ribonucleoside-diphosphate reductase complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleoside diphosphate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleoside triphosphate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleotide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>kidney development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule interconversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0004796</id>
      <name>DNA</name>
      <organism>Humans</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A352</ref-id>
            <pubmed-id>19715446</pubmed-id>
            <citation>Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.</citation>
          </article>
          <article>
            <ref-id>A353</ref-id>
            <pubmed-id>17852710</pubmed-id>
            <citation>Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.</citation>
          </article>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
          <article>
            <ref-id>A6595</ref-id>
            <pubmed-id>16316309</pubmed-id>
            <citation>Kline JP, Larson RA: Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005 Dec;6(15):2711-8.</citation>
          </article>
          <article>
            <ref-id>A6596</ref-id>
            <pubmed-id>14722255</pubmed-id>
            <citation>Hartman WR, Hentosh P: The antileukemia drug 2-chloro-2'-deoxyadenosine: an intrinsic transcriptional antagonist. Mol Pharmacol. 2004 Jan;65(1):227-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
    <target position="5">
      <id>BE0000546</id>
      <name>DNA polymerase alpha catalytic subunit</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
          <article>
            <ref-id>A6595</ref-id>
            <pubmed-id>16316309</pubmed-id>
            <citation>Kline JP, Larson RA: Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005 Dec;6(15):2711-8.</citation>
          </article>
          <article>
            <ref-id>A15624</ref-id>
            <pubmed-id>9923554</pubmed-id>
            <citation>Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M: Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol. 1999;43(3):233-40.</citation>
          </article>
          <article>
            <ref-id>A6596</ref-id>
            <pubmed-id>14722255</pubmed-id>
            <citation>Hartman WR, Hentosh P: The antileukemia drug 2-chloro-2'-deoxyadenosine: an intrinsic transcriptional antagonist. Mol Pharmacol. 2004 Jan;65(1):227-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P09884" source="Swiss-Prot">
        <name>DNA polymerase alpha catalytic subunit</name>
        <general-function>Protein kinase binding</general-function>
        <specific-function>Plays an essential role in the initiation of DNA replication. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1/p180, a regulatory subunit POLA2/p70 and two primase subunits PRIM1/p49 and PRIM2/p58) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. The reason this transfer occurs is because the polymerase alpha has limited processivity and lacks intrinsic 3' exonuclease activity for proofreading error, and therefore is not well suited for replicating long complexes.</specific-function>
        <gene-name>POLA1</gene-name>
        <locus/>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.59</theoretical-pi>
        <molecular-weight>165911.405</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9173</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>POLA1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X06745</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35568</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P09884</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPOLA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.7.7</synonym>
          <synonym>DNA polymerase alpha catalytic subunit p180</synonym>
          <synonym>POLA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016127|DNA polymerase alpha catalytic subunit
MAPVHGDDSLSDSGSFVSSRARREKKSKKGRQEALERLKKAKAGEKYKYEVEDFTGVYEE
VDEEQYSKLVQARQDDDWIVDDDGIGYVEDGREIFDDDLEDDALDADEKGKDGKARNKDK
RNVKKLAVTKPNNIKSMFIACAGKKTADKAVDLSKDGLLGDILQDLNTETPQITPPPVMI
LKKKRSIGASPNPFSVHTATAVPSGKIASPVSRKEPPLTPVPLKRAEFAGDDVQVESTEE
EQESGAMEFEDGDFDEPMEVEEVDLEPMAAKAWDKESEPAEEVKQEADSGKGTVSYLGSF
LPDVSCWDIDQEGDSSFSVQEVQVDSSHLPLVKGADEEQVFHFYWLDAYEDQYNQPGVVF
LFGKVWIESAETHVSCCVMVKNIERTLYFLPREMKIDLNTGKETGTPISMKDVYEEFDEK
IATKYKIMKFKSKPVEKNYAFEIPDVPEKSEYLEVKYSAEMPQLPQDLKGETFSHVFGTN
TSSLELFLMNRKIKGPCWLEVKSPQLLNQPVSWCKVEAMALKPDLVNVIKDVSPPPLVVM
AFSMKTMQNAKNHQNEIIAMAALVHHSFALDKAAPKPPFQSHFCVVSKPKDCIFPYAFKE
VIEKKNVKVEVAATERTLLGFFLAKVHKIDPDIIVGHNIYGFELEVLLQRINVCKAPHWS
KIGRLKRSNMPKLGGRSGFGERNATCGRMICDVEISAKELIRCKSYHLSELVQQILKTER
VVIPMENIQNMYSESSQLLYLLEHTWKDAKFILQIMCELNVLPLALQITNIAGNIMSRTL
MGGRSERNEFLLLHAFYENNYIVPDKQIFRKPQQKLGDEDEEIDGDTNKYKKGRKKAAYA
GGLVLDPKVGFYDKFILLLDFNSLYPSIIQEFNICFTTVQRVASEAQKVTEDGEQEQIPE
LPDPSLEMGILPREIRKLVERRKQVKQLMKQQDLNPDLILQYDIRQKALKLTANSMYGCL
GFSYSRFYAKPLAALVTYKGREILMHTKEMVQKMNLEVIYGDTDSIMINTNSTNLEEVFK
LGNKVKSEVNKLYKLLEIDIDGVFKSLLLLKKKKYAALVVEPTSDGNYVTKQELKGLDIV
RRDWCDLAKDTGNFVIGQILSDQSRDTIVENIQKRLIEIGENVLNGSVPVSQFEINKALT
KDPQDYPDKKSLPHVHVALWINSQGGRKVKAGDTVSYVICQDGSNLTASQRAYAPEQLQK
QDNLTIDTQYYLAQQIHPVVARICEPIDGIDAVLIATWLGLDPTQFRVHHYHKDEENDAL
LGGPAQLTDEEKYRDCERFKCPCPTCGTENIYDNVFDGSGTDMEPSLYRCSNIDCKASPL
TFTVQLSNKLIMDIRRFIKKYYDGWLICEEPTCRNRTRHLPLQFSRTGPLCPACMKATLQ
PEYSDKSLYTQLCFYRYIFDAECALEKLTTDHEKDKLKKQFFTPKVLQDYRKLKNTAEQF
LSRSGYSEVNLSKLFAGCAVKS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016128|DNA polymerase alpha catalytic subunit (POLA1)
ATGGCACCTGTGCACGGCGACGACTCTCTGTCAGATTCAGGGAGTTTTGTATCTTCTCGA
GCCCGGCGAGAAAAAAAATCAAAGAAGGGGCGCCAAGAAGCCCTAGAAAGACTGAAAAAG
GCTAAAGCTGGTGAGAAGTATAAATATGAAGTCGAGGACTTCACAGGTGTTTATGAAGAA
GTTGATGAAGAACAGTATTCGAAGCTGGTTCAGGCACGCCAGGATGATGACTGGATTGTG
GATGATGATGGTATTGGCTATGTGGAAGATGGCCGAGAGATTTTTGATGATGACCTTGAA
GATGATGCCCTTGATGCTGATGAGAAAGGAAAAGATGGTAAAGCACGCAATAAAGACAAG
AGGAATGTAAAGAAGCTCGCAGTGACAAAACCGAACAACATTAAGTCAATGTTCATTGCT
TGTGCTGGAAAGAAAACTGCAGATAAAGCTGTAGACTTGTCCAAGGATGGTCTGCTAGGT
GACATTCTACAGGATCTTAACACTGAGACACCTCAAATAACTCCACCACCTGTAATGATA
CTGAAGAAGAAAAGATCCATTGGAGCTTCACCGAATCCTTTCTCTGTGCACACCGCCACG
GCAGTTCCTTCAGGAAAAATTGCTTCCCCTGTCTCCAGAAAGGAGCCTCCATTAACTCCT
GTTCCTCTTAAACGTGCTGAATTTGCTGGCGATGATGTACAGGTCGAGAGTACAGAAGAA
GAGCAGGAGTCAGGGGCAATGGAGTTTGAAGATGGTGACTTTGATGAGCCCATGGAAGTT
GAAGAGGTGGACCTGGAGCCTATGGCTGCCAAGGCTTGGGACAAAGAGAGTGAGCCAGCA
GAGGAAGTGAAACAAGAGGCGGATTCTGGGAAAGGGACCGTGTCCTACTTAGGAAGTTTT
CTCCCGGATGTCTCTTGTTGGGACATTGATCAAGAAGGTGATAGCAGTTTCTCAGTGCAA
GAAGTTCAAGTGGATTCCAGTCACCTCCCATTGGTAAAAGGGGCAGATGAGGAACAAGTA
TTCCACTTTTATTGGTTGGATGCTTATGAGGATCAGTACAACCAACCAGGTGTGGTATTT
CTGTTTGGGAAAGTTTGGATTGAATCAGCCGAGACCCATGTGAGCTGTTGTGTCATGGTG
AAAAATATCGAGCGAACGCTTTACTTCCTTCCCCGTGAAATGAAAATTGATCTAAATACG
GGGAAAGAAACAGGAACTCCAATTTCAATGAAGGATGTTTATGAGGAATTTGATGAGAAA
ATAGCAACAAAATATAAAATTATGAAGTTCAAGTCTAAGCCAGTGGAAAAGAACTATGCT
TTTGAGATACCTGATGTTCCAGAAAAATCTGAGTACTTGGAAGTTAAATACTCGGCTGAA
ATGCCACAGCTTCCTCAAGATTTGAAAGGAGAAACTTTTTCTCATGTATTTGGGACCAAC
ACATCTAGCCTGGAACTGTTCTTGATGAACAGAAAGATCAAAGGACCTTGTTGGCTTGAA
GTAAAAAGTCCACAGCTCTTGAATCAGCCAGTCAGTTGGTGTAAAGTTGAGGCAATGGCT
TTGAAACCAGACCTGGTGAATGTAATTAAGGATGTCAGTCCACCACCGCTTGTCGTGATG
GCTTTCAGCATGAAGACAATGCAGAATGCAAAGAACCATCAAAATGAGATTATTGCTATG
GCAGCTTTGGTCCATCACAGTTTTGCATTGGATAAAGCAGCCCCAAAGCCTCCCTTTCAG
TCACACTTCTGTGTTGTGTCTAAACCAAAGGACTGTATTTTTCCATATGCTTTCAAAGAA
GTCATTGAGAAAAAGAATGTGAAGGTTGAGGTTGCTGCAACAGAAAGAACACTGCTAGGT
TTTTTCCTTGCAAAAGTTCACAAAATTGATCCTGATATCATTGTGGGTCATAATATTTAT
GGGTTTGAACTGGAAGTACTACTGCAGAGAATTAATGTGTGCAAAGCTCCTCACTGGTCC
AAGATAGGTCGACTGAAGCGATCCAACATGCCAAAGCTTGGGGGCCGGAGTGGATTTGGT
GAAAGAAATGCTACCTGTGGTCGAATGATCTGTGATGTGGAAATTTCAGCAAAGGAATTG
ATTCGTTGTAAAAGCTACCATCTGTCTGAACTTGTTCAGCAGATTCTAAAAACTGAAAGG
GTTGTAATCCCAATGGAAAATATACAAAATATGTACAGTGAATCTTCTCAACTGTTATAC
CTGTTGGAACACACCTGGAAAGATGCCAAGTTCATTTTGCAGATCATGTGTGAGCTAAAT
GTTCTTCCATTAGCATTGCAGATCACTAACATCGCTGGGAACATTATGTCCAGGACGCTG
ATGGGTGGACGATCCGAGCGTAACGAGTTCTTGTTGCTTCATGCATTTTACGAAAACAAC
TATATTGTGCCTGACAAGCAGATTTTCAGAAAGCCTCAGCAAAAACTGGGAGATGAAGAT
GAAGAAATTGATGGAGATACCAATAAATACAAGAAAGGACGTAAGAAAGCAGCTTATGCT
GGAGGCTTGGTTTTGGACCCCAAAGTTGGTTTTTATGATAAGTTCATTTTGCTTCTGGAC
TTCAACAGTCTATATCCTTCCATCATTCAGGAATTTAACATTTGTTTTACAACAGTACAA
AGAGTTGCTTCAGAGGCACAGAAAGTTACAGAGGATGGAGAACAAGAACAGATCCCTGAG
TTGCCAGATCCAAGCTTAGAAATGGGCATTTTGCCCAGAGAGATCCGGAAACTGGTAGAA
CGGAGAAAACAAGTCAAACAGCTAATGAAACAGCAAGACTTAAATCCAGACCTTATTCTT
CAGTATGACATTCGACAGAAGGCTTTGAAGCTCACAGCGAACAGTATGTATGGTTGCCTG
GGATTTTCCTATAGCAGATTTTACGCCAAACCACTGGCTGCCTTGGTGACATACAAAGGA
AGGGAGATTTTGATGCATACGAAAGAGATGGTACAAAAGATGAATCTTGAAGTTATTTAT
GGAGATACAGATTCAATTATGATAAACACCAATAGCACCAATCTGGAAGAAGTATTTAAG
TTGGGAAACAAGGTAAAAAGTGAAGTGAATAAGTTGTACAAACTGCTTGAAATAGACATT
GATGGGGTTTTCAAGTCTCTGCTACTGCTGAAAAAAAAGAAGTACGCTGCTCTGGTTGTT
GAGCCAACGTCGGATGGGAATTATGTCACCAAACAGGAGCTCAAAGGATTAGATATAGTT
AGAAGAGATTGGTGTGATCTTGCTAAAGACACTGGAAACTTTGTGATTGGCCAGATTCTT
TCTGATCAAAGCCGGGACACTATAGTGGAAAACATTCAGAAGAGGCTGATAGAAATTGGA
GAAAATGTGCTAAATGGCAGTGTCCCAGTGAGCCAGTTTGAAATTAACAAGGCATTGACA
AAGGATCCCCAGGATTACCCTGATAAAAAAAGCCTACCTCATGTACATGTTGCCCTCTGG
ATAAATTCTCAAGGAGGCAGAAAGGTGAAAGCTGGAGATACTGTGTCATATGTCATCTGT
CAGGATGGATCAAACCTCACTGCAAGTCAGAGGGCCTATGCGCCTGAGCAGCTGCAGAAA
CAGGATAATCTAACCATTGACACCCAGTACTACCTGGCCCAGCAGATCCACCCAGTCGTG
GCTCGGATCTGTGAACCAATAGACGGAATTGATGCTGTCCTCATTGCAACGTGGTTGGGA
CTTGACCCCACCCAATTTAGAGTTCATCATTATCATAAAGATGAAGAGAATGATGCTCTA
CTTGGTGGCCCAGCACAGCTCACTGATGAAGAGAAATACAGGGACTGTGAAAGATTCAAA
TGTCCATGCCCTACATGTGGAACTGAGAATATTTATGATAATGTCTTTGATGGTTCGGGA
ACAGATATGGAGCCCAGCTTGTATCGTTGCAGTAACATCGATTGTAAGGCTTCACCTCTG
ACCTTTACAGTACAACTGAGCAACAAATTGATCATGGACATTAGACGTTTCATTAAAAAG
TACTATGATGGCTGGTTGATATGTGAAGAGCCAACCTGTCGCAATCGAACTCGTCACCTT
CCCCTTCAATTCTCCCGAACTGGGCCTCTTTGCCCAGCCTGCATGAAAGCTACACTTCAA
CCAGAGTATTCTGACAAGTCCCTGTACACCCAGCTGTGCTTTTACCGGTACATTTTTGAT
GCGGAGTGTGCACTGGAGAAACTTACTACCGATCATGAGAAAGATAAATTGAAGAAGCAA
TTTTTTACCCCCAAAGTTCTGCAGGACTACAGAAAACTCAAGAACACAGCAGAGCAATTC
TTGTCCCGAAGTGGCTACTCCGAAGTGAATCTGAGCAAACTCTTCGCTGGTTGTGCCGTG
AAATCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00136</identifier>
            <name>DNA_pol_B</name>
          </pfam>
          <pfam>
            <identifier>PF03104</identifier>
            <name>DNA_pol_B_exo1</name>
          </pfam>
          <pfam>
            <identifier>PF12254</identifier>
            <name>DNA_pol_alpha_N</name>
          </pfam>
          <pfam>
            <identifier>PF08996</identifier>
            <name>zf-DNA_Pol</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>alpha DNA polymerase</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3'-5' exonuclease activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>4 iron, 4 sulfur cluster binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-directed DNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleoside binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication initiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication, synthesis of RNA primer</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA strand elongation involved in DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>double-strand break repair via nonhomologous end joining</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lagging strand elongation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leading strand elongation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance via recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance via semi-conservative replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0003614</id>
      <name>DNA polymerase epsilon catalytic subunit A</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q07864" source="Swiss-Prot">
        <name>DNA polymerase epsilon catalytic subunit A</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Participates in DNA repair and in chromosomal DNA replication.</specific-function>
        <gene-name>POLE</gene-name>
        <locus>12q24.3</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.35</theoretical-pi>
        <molecular-weight>261515.525</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L09561</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3192938</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q07864</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPOE1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.7.7</synonym>
          <synonym>DNA polymerase II subunit A</synonym>
          <synonym>POLE1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006953|DNA polymerase epsilon catalytic subunit A
MSLRSGGRRRADPGADGEASRDDGATSSVSALKRLERSQWTDKMDLRFGFERLKEPGEKT
GWLINMHPTEILDEDKRLGSAVDYYFIQDDGSRFKVALPYKPYFYIATRKGCEREVSSFL
SKKFQGKIAKVETVPKEDLDLPNHLVGLKRNYIRLSFHTVEDLVKVRKEISPAVKKNREQ
DHASDAYTALLSSVLQRGGVITDEEETSKKIADQLDNIVDMREYDVPYHIRLSIDLKIHV
AHWYNVRYRGNAFPVEITRRDDLVERPDPVVLAFDIETTKLPLKFPDAETDQIMMISYMI
DGQGYLITNREIVSEDIEDFEFTPKPEYEGPFCVFNEPDEAHLIQRWFEHVQETKPTIMV
TYNGDFFDWPFVEARAAVHGLSMQQEIGFQKDSQGEYKAPQCIHMDCLRWVKRDSYLPVG
SHNLKAAAKAKLGYDPVELDPEDMCRMATEQPQTLATYSVSDAVATYYLYMKYVHPFIFA
LCTIIPMEPDEVLRKGSGTLCEALLMVQAFHANIIFPNKQEQEFNKLTDDGHVLDSETYV
GGHVEALESGVFRSDIPCRFRMNPAAFDFLLQRVEKTLRHALEEEEKVPVEQVTNFEEVC
DEIKSKLASLKDVPSRIECPLIYHLDVGAMYPNIILTNRLQPSAMVDEATCAACDFNKPG
ANCQRKMAWQWRGEFMPASRSEYHRIQHQLESEKFPPLFPEGPARAFHELSREEQAKYEK
RRLADYCRKAYKKIHITKVEERLTTICQRENSFYVDTVRAFRDRRYEFKGLHKVWKKKLS
AAVEVGDAAEVKRCKNMEVLYDSLQLAHKCILNSFYGYVMRKGARWYSMEMAGIVCFTGA
NIITQARELIEQIGRPLELDTDGIWCVLPNSFPENFVFKTTNVKKPKVTISYPGAMLNIM
VKEGFTNDQYQELAEPSSLTYVTRSENSIFFEVDGPYLAMILPASKEEGKKLKKRYAVFN
EDGSLAELKGFEVKRRGELQLIKIFQSSVFEAFLKGSTLEEVYGSVAKVADYWLDVLYSK
AANMPDSELFELISENRSMSRKLEDYGEQKSTSISTAKRLAEFLGDQMVKDAGLSCRYII
SRKPEGSPVTERAIPLAIFQAEPTVRKHFLRKWLKSSSLQDFDIRAILDWDYYIERLGSA
IQKIITIPAALQQVKNPVPRVKHPDWLHKKLLEKNDVYKQKKISELFTLEGRRQVTMAEA
SEDSPRPSAPDMEDFGLVKLPHPAAPVTVKRKRVLWESQEESQDLTPTVPWQEILGQPPA
LGTSQEEWLVWLRFHKKKWQLQARQRLARRKRQRLESAEGVLRPGAIRDGPATGLGSFLR
RTARSILDLPWQIVQISETSQAGLFRLWALVGSDLHCIRLSIPRVFYVNQRVAKAEEGAS
YRKVNRVLPRSNMVYNLYEYSVPEDMYQEHINEINAELSAPDIEGVYETQVPLLFRALVH
LGCVCVVNKQLVRHLSGWEAETFALEHLEMRSLAQFSYLEPGSIRHIYLYHHAQAHKALF
GIFIPSQRRASVFVLDTVRSNQMPSLGALYSAEHGLLLEKVGPELLPPPKHTFEVRAETD
LKTICRAIQRFLLAYKEERRGPTLIAVQSSWELKRLASEIPVLEEFPLVPICVADKINYG
VLDWQRHGARRMIRHYLNLDTCLSQAFEMSRYFHIPIGNLPEDISTFGSDLFFARHLQRH
NHLLWLSPTARPDLGGKEADDNCLVMEFDDQATVEINSSGCYSTVCVELDLQNLAVNTIL
QSHHVNDMEGADSMGISFDVIQQASLEDMITGGQAASAPASYDETALCSNTFRILKSMVV
GWVKEITQYHNIYADNQVMHFYRWLRSPSSLLHDPALHRTLHNMMKKLFLQLIAEFKRLG
SSVIYANFNRIILCTKKRRVEDAIAYVEYITSSIHSKETFHSLTISFSRCWEFLLWMDPS
NYGGIKGKVSSRIHCGLQDSQKAGGAEDEQENEDDEEERDGEEEEEAEESNVEDLLENNW
NILQFLPQAASCQNYFLMIVSAYIVAVYHCMKDGLRRSAPGSTPVRRRGASQLSQEAEGA
VGALPGMITFSQDYVANELTQSFFTITQKIQKKVTGSRNSTELSEMFPVLPGSHLLLNNP
ALEFIKYVCKVLSLDTNITNQVNKLNRDLLRLVDVGEFSEEAQFRDPCRSYVLPEVICRS
CNFCRDLDLCKDSSFSEDGAVLPQWLCSNCQAPYDSSAIEMTLVEVLQKKLMAFTLQDLV
CLKCRGVKETSMPVYCSCAGDFALTIHTQVFMEQIGIFRNIAQHYGMSYLLETLEWLLQK
NPQLGH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012512|DNA polymerase epsilon catalytic subunit A (POLE)
ATGTCTCTGAGGAGCGGCGGGCGGCGGCGCGCGGACCCAGGCGCGGATGGCGAGGCCAGC
AGGGATGATGGCGCCACTTCCTCAGTTTCGGCACTCAAGCGCCTGGAACGGAGTCAGTGG
ACGGATAAGATGGATTTGCGGTTTGGTTTTGAGCGGCTGAAGGAGCCTGGTGAGAAGACA
GGCTGGCTCATTAACATGCATCCTACCGAGATTTTAGATGAAGATAAGCGCTTAGGCAGT
GCAGTGGATTACTACTTTATTCAAGATGACGGAAGCAGATTTAAGGTGGCTTTGCCCTAT
AAACCGTATTTCTACATTGCGACCAGAAAGGGTTGTGAGCGAGAAGTTTCATCTTTTCTC
TCCAAGAAGTTTCAGGGCAAAATTGCAAAAGTGGAGACTGTCCCCAAAGAGGATCTGGAC
TTGCCAAATCACTTGGTGGGTTTGAAGCGAAATTACATCAGGCTGTCCTTCCACACTGTG
GAGGATCTTGTCAAAGTGAGGAAGGAGATCTCCCCTGCCGTGAAGAAGAACAGGGAGCAG
GATCACGCCAGCGACGCGTACACAGCTCTGCTTTCCAGTGTTCTGCAGAGGGGCGGTGTC
ATTACTGATGAAGAGGAAACCTCTAAGAAGATAGCTGACCAGTTGGACAACATTGTGGAC
ATGCGCGAGTACGATGTTCCCTACCACATCCGCCTCTCCATTGACCTGAAGATCCACGTG
GCTCATTGGTACAATGTCAGATACCGAGGAAATGCTTTTCCGGTAGAAATCACCCGCCGA
GATGACCTTGTTGAACGACCTGACCCTGTGGTTTTGGCATTTGACATTGAGACGACCAAA
CTGCCCCTCAAGTTTCCTGATGCTGAGACAGACCAGATTATGATGATTTCCTACATGATC
GATGGCCAGGGCTACCTCATCACCAACAGGGAGATTGTTTCAGAAGATATTGAAGATTTT
GAGTTCACCCCCAAGCCAGAATATGAAGGCCCCTTTTGTGTCTTCAATGAACCCGATGAG
GCTCATCTGATCCAAAGGTGGTTTGAACACGTCCAGGAGACCAAACCCACCATCATGGTC
ACCTACAACGGGGACTTTTTTGACTGGCCATTTGTGGAGGCCCGGGCAGCAGTCCACGGT
CTGAGCATGCAGCAGGAGATAGGCTTCCAGAAGGACAGCCAGGGGGAGTACAAGGCGCCC
CAGTGCATCCACATGGACTGCCTCAGGTGGGTGAAGAGGGACAGTTACCTTCCTGTGGGC
AGTCATAATCTCAAGGCGGCCGCCAAGGCCAAGCTAGGCTATGATCCCGTGGAGCTAGAC
CCGGAGGACATGTGCCGGATGGCCACGGAGCAGCCCCAGACTCTGGCCACGTATTCTGTG
TCAGATGCTGTCGCCACTTACTACCTGTACATGAAGTACGTCCACCCATTCATCTTTGCT
CTGTGCACCATTATTCCCATGGAGCCCGACGAGGTGCTGCGGAAGGGCTCTGGCACTCTG
TGTGAGGCCTTGCTGATGGTGCAGGCCTTCCACGCCAACATCATCTTCCCCAACAAGCAA
GAGCAGGAGTTCAATAAGCTGACGGACGACGGACACGTGCTGGACTCTGAGACCTACGTC
GGGGGCCACGTGGAGGCCCTCGAGTCTGGGGTTTTCCGCAGCGATATCCCTTGCCGGTTT
AGGATGAATCCTGCCGCCTTTGACTTCCTGCTGCAGCGGGTTGAGAAGACCTTGCGCCAC
GCCCTTGAGGAAGAGGAGAAAGTGCCTGTGGAGCAAGTCACCAACTTTGAAGAGGTGTGT
GATGAGATTAAGAGCAAGCTTGCCTCCCTGAAGGACGTTCCCAGCCGCATCGAGTGTCCA
CTCATCTACCACCTGGACGTGGGGGCCATGTACCCCAACATCATCCTGACCAACCGCCTG
CAGCCCTCTGCCATGGTGGACGAAGCCACCTGTGCTGCCTGTGACTTCAATAAGCCTGGA
GCAAACTGCCAGCGGAAGATGGCCTGGCAGTGGAGGGGCGAGTTCATGCCAGCCAGTCGC
AGCGAATACCATCGGATCCAGCACCAGCTGGAGTCAGAGAAGTTCCCCCCCTTGTTCCCA
GAGGGGCCAGCTCGGGCCTTTCATGAACTGTCCCGCGAGGAACAGGCGAAATACGAGAAG
AGAAGGCTGGCGGATTACTGCCGGAAAGCCTACAAGAAGATCCACATCACCAAGGTGGAA
GAGCGTCTCACCACCATCTGCCAGCGGGAAAACTCCTTCTACGTGGACACCGTGCGTGCC
TTCCGGGACAGGCGTTACGAGTTCAAAGGGCTCCACAAGGTGTGGAAAAAGAAGCTCTCG
GCGGCCGTGGAGGTGGGCGACGCGGCTGAGGTGAAGCGCTGCAAGAACATGGAGGTGCTG
TATGACTCGCTGCAGCTGGCCCACAAGTGCATCCTGAACTCCTTCTATGGCTATGTCATG
CGCAAGGGGGCTCGCTGGTACTCCATGGAGATGGCTGGCATCGTCTGCTTCACAGGGGCC
AACATCATCACCCAGGCACGGGAGCTGATCGAGCAGATTGGGAGGCCCTTAGAGCTGGAC
ACAGATGGTATATGGTGCGTCCTGCCCAACAGCTTCCCAGAAAATTTTGTCTTCAAGACG
ACCAATGTGAAGAAGCCCAAAGTGACCATCTCCTACCCAGGCGCCATGTTGAACATCATG
GTCAAGGAAGGCTTCACCAATGACCAGTACCAGGAGCTGGCTGAGCCGTCCTCACTCACC
TACGTCACCCGCTCAGAGAACAGCATCTTTTTTGAGGTTGATGGGCCCTACCTTGCCATG
ATTCTTCCAGCCTCCAAGGAAGAAGGCAAGAAATTGAAGAAGAGGTATGCTGTGTTCAAT
GAAGACGGTTCTCTGGCTGAGCTCAAGGGCTTTGAGGTCAAACGCCGCGGGGAACTGCAG
CTGATTAAGATCTTCCAATCCTCGGTGTTTGAGGCCTTCCTCAAGGGCAGCACGCTGGAA
GAGGTGTATGGCTCTGTAGCCAAGGTGGCTGACTACTGGCTGGACGTGCTGTACAGCAAG
GCAGCCAACATGCCTGACTCTGAGCTATTCGAGCTCATCTCTGAGAACCGTTCCATGTCT
CGGAAGCTGGAAGATTACGGGGAGCAGAAGTCTACGTCCATCAGCACAGCAAAGCGCCTG
GCCGAGTTCCTGGGAGACCAGATGGTCAAGGATGCAGGGCTGAGTTGCCGCTACATCATC
TCCCGCAAGCCCGAGGGCTCCCCTGTCACGGAGAGGGCCATCCCACTTGCCATTTTCCAA
GCAGAGCCCACGGTGAGGAAGCACTTTCTCCGGAAATGGCTCAAGAGCTCTTCCCTTCAA
GACTTTGATATTCGAGCAATTCTGGATTGGGACTACTACATTGAGCGGCTGGGAAGCGCC
ATCCAGAAGATCATCACCATCCCTGCGGCCCTGCAGCAGGTAAAGAACCCAGTGCCACGT
GTCAAACACCCCGACTGGCTGCACAAAAAACTGCTGGAGAAGAATGATGTCTACAAGCAG
AAGAAGATCAGTGAGCTCTTCACCCTGGAGGGCAGGAGACAGGTCACGATGGCCGAGGCC
TCAGAAGACAGTCCGAGGCCAAGTGCTCCTGACATGGAGGACTTCGGCCTCGTAAAGCTG
CCTCACCCAGCAGCCCCTGTCACTGTGAAGAGGAAGCGAGTTCTTTGGGAGAGCCAGGAG
GAGTCCCAGGACCTCACGCCGACTGTGCCCTGGCAGGAAATCTTGGGGCAGCCTCCCGCC
CTGGGAACCAGCCAGGAGGAATGGCTTGTCTGGCTCCGGTTCCACAAGAAGAAGTGGCAG
CTGCAGGCCCGGCAGCGCCTCGCCCGCAGGAAGAGGCAGCGTCTGGAGTCGGCAGAGGGT
GTGCTCAGGCCCGGGGCCATCCGGGATGGTCCTGCCACGGGGCTGGGGAGCTTCTTGCGA
AGAACTGCCCGCAGCATCCTGGACCTTCCGTGGCAGATTGTGCAGATCAGCGAGACCAGC
CAGGCCGGCCTGTTCAGGCTGTGGGCGCTCGTTGGCAGTGACTTGCACTGCATCAGGCTG
AGCATCCCCCGTGTGTTCTACGTGAACCAGCGAGTCGCTAAAGCGGAGGAGGGTGCTTCG
TATCGCAAGGTAAATCGGGTCCTTCCTCGCTCCAACATGGTCTACAATCTCTATGAGTAT
TCAGTGCCAGAGGACATGTACCAGGAACACATCAACGAGATCAACGCTGAGCTGTCAGCG
CCAGACATCGAGGGCGTATATGAGACTCAGGTTCCGTTACTGTTCCGGGCCCTGGTGCAC
CTGGGCTGTGTGTGTGTGGTCAATAAACAGCTGGTGAGGCACCTTTCAGGCTGGGAAGCA
GAGACCTTTGCTCTTGAGCACCTGGAGATGCGCTCTCTGGCCCAGTTCAGCTACCTGGAA
CCAGGGAGTATCCGCCATATCTACCTGTACCACCACGCACAGGCCCACAAAGCGCTCTTC
GGGATCTTCATCCCCTCACAGCGCAGGGCATCCGTCTTTGTGCTGGACACTGTGCGCAGC
AACCAGATGCCCAGCCTTGGCGCCCTGTACTCAGCAGAGCACGGCCTCCTCCTGGAGAAG
GTGGGCCCTGAGCTCCTGCCACCCCCCAAACACACCTTCGAAGTTCGGGCAGAAACTGAC
CTGAAGACCATCTGCAGAGCCATCCAGCGATTCCTGCTCGCCTACAAGGAGGAGCGCCGG
GGGCCCACACTCATCGCTGTTCAGTCCAGCTGGGAGCTGAAGAGGCTGGCCAGTGAAATT
CCTGTCTTGGAGGAATTCCCACTGGTGCCTATCTGTGTGGCTGACAAGATCAACTATGGG
GTCCTGGACTGGCAGCGCCATGGAGCCCGGCGCATGATCCGTCACTACCTCAACCTGGAC
ACCTGCCTGTCGCAGGCCTTCGAGATGAGCAGGTACTTTCACATTCCCATTGGGAACCTA
CCAGAGGACATCTCCACATTCGGCTCCGACCTCTTCTTTGCCCGCCACCTCCAGCGCCAC
AACCACCTGCTCTGGCTGTCCCCTACAGCCCGCCCTGACCTGGGTGGAAAGGAGGCTGAT
GACAACTGTCTTGTCATGGAGTTCGATGACCAAGCCACTGTTGAGATCAACAGTTCAGGC
TGTTACTCCACAGTGTGTGTGGAGCTGGACCTTCAGAACCTGGCCGTCAACACCATTCTC
CAGTCTCACCATGTCAACGACATGGAGGGGGCCGACAGCATGGGGATCAGCTTCGACGTG
ATCCAGCAGGCCTCCCTGGAGGACATGATCACGGGTGGTCAGGCTGCCAGTGCCCCGGCC
AGCTACGATGAGACAGCCCTGTGCTCTAACACCTTCAGGATCCTGAAGAGCATGGTCGTG
GGCTGGGTGAAGGAGATCACCCAGTACCACAACATCTATGCAGACAACCAGGTGATGCAC
TTCTACCGCTGGCTTCGGTCGCCATCCTCTCTGCTTCATGACCCTGCCCTGCACCGCACA
CTCCACAACATGATGAAGAAGCTCTTCCTGCAGCTCATCGCTGAGTTCAAGCGCCTGGGG
TCATCAGTCATCTACGCCAACTTCAACCGCATCATCCTCTGTACAAAGAAGCGCCGTGTG
GAAGATGCCATCGCTTACGTGGAGTACATCACCAGCAGCATCCATTCAAAGGAGACCTTC
CATTCTCTGACAATTTCTTTCTCTCGATGCTGGGAATTTCTTCTCTGGATGGATCCATCT
AACTATGGCGGAATCAAAGGAAAAGTTTCATCTCGTATTCACTGTGGACTGCAAGACTCC
CAGAAAGCAGGGGGAGCAGAGGATGAGCAGGAAAATGAGGACGATGAGGAGGAAAGAGAT
GGGGAGGAGGAGGAAGAGGCGGAGGAATCCAACGTGGAGGATTTACTGGAAAACAACTGG
AACATTTTGCAGTTTTTGCCACAGGCAGCCTCCTGCCAGAACTACTTCCTCATGATTGTT
TCAGCGTACATCGTGGCCGTGTACCACTGCATGAAGGACGGGCTGAGGCGCAGTGCTCCA
GGGAGCACCCCCGTGAGGAGGAGGGGGGCCAGCCAGCTCTCCCAGGAGGCCGAGGGGGCG
GTCGGAGCCCTTCCCGGAATGATCACCTTCTCTCAGGATTATGTCGCAAATGAGCTCACT
CAGAGCTTCTTCACCATCACTCAGAAGATTCAGAAGAAAGTCACAGGCTCTCGGAACTCC
ACTGAGCTCTCAGAGATGTTTCCTGTCCTCCCCGGTTCCCACTTGCTGCTCAATAACCCT
GCCCTGGAGTTCATCAAATACGTGTGCAAGGTGCTGTCCCTGGACACCAACATCACAAAC
CAGGTGAATAAGCTGAACCGAGACCTGCTTCGCCTGGTGGATGTCGGCGAGTTCTCCGAG
GAGGCCCAGTTCCGAGACCCCTGCCGCTCCTACGTGCTTCCTGAGGTCATCTGCCGCAGC
TGTAACTTCTGCCGCGACCTGGACCTGTGTAAAGACTCTTCCTTCTCAGAGGATGGGGCG
GTCCTGCCTCAGTGGCTCTGCTCCAACTGTCAGGCGCCCTACGACTCCTCTGCCATCGAG
ATGACGCTGGTGGAAGTTCTACAGAAGAAGCTGATGGCCTTCACCCTGCAGGACCTGGTC
TGCCTGAAGTGCCGCGGGGTGAAGGAGACCAGCATGCCTGTGTACTGCAGCTGCGCGGGA
GACTTCGCCCTCACCATCCACACCCAGGTCTTCATGGAACAGATCGGAATATTCCGGAAC
ATTGCCCAGCACTACGGCATGTCGTACCTCCTGGAGACCCTGGAGTGGCTGCTGCAGAAG
AACCCACAGCTGGGCCATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00136</identifier>
            <name>DNA_pol_B</name>
          </pfam>
          <pfam>
            <identifier>PF03104</identifier>
            <name>DNA_pol_B_exo1</name>
          </pfam>
          <pfam>
            <identifier>PF08490</identifier>
            <name>DUF1744</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>epsilon DNA polymerase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3'-5' exonuclease activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>4 iron, 4 sulfur cluster binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-directed DNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>base-excision repair, gap-filling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication initiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA synthesis involved in DNA repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide-excision repair, DNA gap filling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance via recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance via semi-conservative replication</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0003615</id>
      <name>DNA polymerase epsilon subunit 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P56282" source="Swiss-Prot">
        <name>DNA polymerase epsilon subunit 2</name>
        <general-function>Dna-directed dna polymerase activity</general-function>
        <specific-function>Participates in DNA repair and in chromosomal DNA replication.</specific-function>
        <gene-name>POLE2</gene-name>
        <locus>14q21-q22</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.3</theoretical-pi>
        <molecular-weight>59536.64</molecular-weight>
        <chromosome-location>14</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9178</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF025840</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2697123</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P56282</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPOE2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.7.7</synonym>
          <synonym>DNA polymerase epsilon subunit B</synonym>
          <synonym>DNA polymerase II subunit 2</synonym>
          <synonym>DPE2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006955|DNA polymerase epsilon subunit 2
MAPERLRSRALSAFKLRGLLLRGEAIKYLTEALQSISELELEDKLEKIINAVEKQPLSSN
MIERSVVEAAVQECSQSVDETIEHVFNIIGAFDIPRFVYNSERKKFLPLLMTNHPAPNLF
GTPRDKAEMFRERYTILHQRTHRHELFTPPVIGSHPDESGSKFQLKTIETLLGSTTKIGD
AIVLGMITQLKEGKFFLEDPTGTVQLDLSKAQFHSGLYTEACFVLAEGWFEDQVFHVNAF
GFPPTEPSSTTRAYYGNINFFGGPSNTSVKTSAKLKQLEEENKDAMFVFLSDVWLDQVEV
LEKLRIMFAGYSPAPPTCFILCGNFSSAPYGKNQVQALKDSLKTLADIICEYPDIHQSSR
FVFVPGPEDPGFGSILPRPPLAESITNEFRQRVPFSVFTTNPCRIQYCTQEITVFREDLV
NKMCRNCVRFPSSNLAIPNHFVKTILSQGHLTPLPLYVCPVYWAYDYALRVYPVPDLLVI
ADKYDPFTTTNTECLCINPGSFPRSGFSFKVFYPSNKTVEDSKLQGF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012513|DNA polymerase epsilon subunit 2 (POLE2)
ATGGCGCCGGAGCGGCTGCGGAGCCGGGCGCTCTCCGCCTTCAAGTTGCGGGGCTTGCTG
CTCCGTGGTGAAGCTATTAAGTACCTCACAGAAGCTCTTCAGTCTATCAGTGAATTAGAG
CTTGAAGATAAACTGGAAAAGATAATTAATGCAGTTGAGAAGCAACCCTTGTCATCAAAC
ATGATTGAACGATCTGTGGTGGAAGCAGCAGTCCAGGAATGCAGTCAGTCTGTTGATGAA
ACTATTCTGTTAATGACCAACCACCCTGCACCAAATTTATTTGGAACACCAAGAGATAAA
GCAGAGATGTTTCGTGAGCGATATACCATTTTGCACCAGAGGACCCACAGGCATGAATTA
TTTACTCCTCCGGTGATAGGTTCTCACCCTGATGAAAGCGGAAGCAAATTCCAGCTTAAA
ACAATAGAAACCTTATTGGGTAGTACAACCAAAATCGGAGATGCGATTGTTCTTGGAATG
ATAACGCAGTTAAAAGAGGGAAAATTTTTTCTGGAAGATCCTACTGGAACAGTCCAACTA
GACCTTAGTAAAGCTCAGTTCCATAGTGGTTTATACACAGAGGCATGCTTTGTCTTAGCA
GAAGGTTGGTTTGAAGATCAAGTGTTTCATGTCAATGCCTTTGGATTTCCACCCACTGAG
CCCTCTAGTACTACTAGGGCATACTATGGAAATATTAATTTTTTTGGAGGTCCTTCTAAT
ACATCTGTGAAGACTTCTGCAAAACTAAAACAGCTAGAAGAGGAGAATAAAGATGCTATG
TTTGTGTTTTTATCTGATGTTTGGTTGGACCAGGTGGAAGTATTGGAAAAACTTCGCATA
ATGTTTGCTGGTTATTCACCAGCACCTCCAACCTGCTTTATTCTGTGTGGTAATTTTTCA
TCTGCACCATATGGAAAAAATCAAGTTCAAGCTTTGAAAGATTCCCTAAAAACTTTGGCA
GATATAATATGTGAATACCCAGATATTCACCAAAGTAGTCGTTTTGTGTTTGTACCTGGT
CCAGAGGATCCTGGATTTGGTTCCATCTTACCAAGGCCACCACTTGCTGAAAGCATCACT
AATGAATTCAGACAAAGGGTACCATTTTCAGTTTTTACTACTAATCCTTGCAGAATTCAG
TACTGTACACAGGAAATTACTGTCTTCCGTGAAGACTTAGTAAATAAAATGTGCAGAAAC
TGCGTCCGTTTTCCTAGCAGCAATTTGGCTATTCCTAATCACTTTGTAAAGACTATCTTA
TCCCAAGGACATCTGACTCCCCTACCTCTTTATGTCTGCCCAGTGTATTGGGCATATGAC
TATGCTTTGAGAGTGTATCCTGTGCCCGATCTACTTGTCATTGCAGACAAATATGATCCT
TTCACTACGACAAATACCGAATGCCTCTGCATAAACCCTGGCTCTTTTCCAAGAAGTGGA
TTTTCATTCAAAGTTTTTTATCCTTCTAATAAGACAGTAGAAGATAGCAAACTTCAAGGC
TTTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF04042</identifier>
            <name>DNA_pol_E_B</name>
          </pfam>
          <pfam>
            <identifier>PF12213</identifier>
            <name>Dpoe2NT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>epsilon DNA polymerase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-directed DNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA repair</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication initiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA-dependent DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>error-prone translesion synthesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance via recombination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>telomere maintenance via semi-conservative replication</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0003617</id>
      <name>DNA polymerase epsilon subunit 3</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9NRF9" source="Swiss-Prot">
        <name>DNA polymerase epsilon subunit 3</name>
        <general-function>Dna-directed dna polymerase activity</general-function>
        <specific-function>Forms a complex with DNA polymerase epsilon subunit CHRAC1 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome-remodeling activity of ISWI/SNF2H and ACF1.</specific-function>
        <gene-name>POLE3</gene-name>
        <locus>9q33</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.38</theoretical-pi>
        <molecular-weight>16859.4</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:13546</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF226077</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>8100806</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NRF9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPOE3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.7.7</synonym>
          <synonym>Arsenic-transactivated protein</synonym>
          <synonym>AsTP</synonym>
          <synonym>CHRAC-17</synonym>
          <synonym>CHRAC17</synonym>
          <synonym>Chromatin accessibility complex 17 kDa protein</synonym>
          <synonym>DNA polymerase epsilon subunit p17</synonym>
          <synonym>DNA polymerase II subunit 3</synonym>
          <synonym>HuCHRAC17</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012514|DNA polymerase epsilon subunit 3
MAERPEDLNLPNAVITRIIKEALPDGVNISKEARSAISRAASVFVLYATSCANNFAMKGK
RKTLNASDVLSAMEEMEFQRFVTPLKEALEAYRREQKGKKEASEQKKKDKDKKTDSEEQD
KSRDEDNDEDEERLEEEEQNEEEEVDN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012515|DNA polymerase epsilon subunit 3 (POLE3)
ATGGCGGAGAGGCCCGAGGACCTAAACCTGCCCAATGCCGTGATCACCAGGATCATCAAG
GAGGCGCTCCCGGACGGTGTCAACATCTCCAAGGAGGCCCGGAGCGCCATCTCCCGCGCC
GCCAGCGTCTTCGTGCTGTACGCCACATCCTGTGCTAACAACTTTGCAATGAAAGGAAAG
CGGAAGACGCTGAATGCCAGTGATGTGCTCTCAGCCATGGAAGAGATGGAGTTCCAGCGG
TTCGTTACCCCATTGAAAGAAGCTCTGGAAGCATATAGGCGGGAGCAGAAAGGCAAGAAG
GAGGCCTCAGAGCAAAAGAAGAAGGACAAAGACAAAAAAACAGACTCGGAAGAGCAAGAC
AAGAGCAGGGATGAGGACAATGATGAAGACGAAGAAAGGCTGGAAGAAGAAGAACAGAAT
GAAGAGGAAGAAGTAGACAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00808</identifier>
            <name>CBFD_NFYB_HMF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>Ada2/Gcn5/Ada3 transcription activator complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>epsilon DNA polymerase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-directed DNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>histone H3 acetylation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="9">
      <id>BE0003616</id>
      <name>DNA polymerase epsilon subunit 4</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9NR33" source="Swiss-Prot">
        <name>DNA polymerase epsilon subunit 4</name>
        <general-function>Dna-directed dna polymerase activity</general-function>
        <specific-function>May play a role in allowing polymerase epsilon to carry out its replication and/or repair function.</specific-function>
        <gene-name>POLE4</gene-name>
        <locus>2p12</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.55</theoretical-pi>
        <molecular-weight>12208.63</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:18755</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>BC031331</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>21411517</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NR33</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPOE4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.7.7</synonym>
          <synonym>DNA polymerase epsilon subunit p12</synonym>
          <synonym>DNA polymerase II subunit 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017158|DNA polymerase epsilon subunit 4
MAAAAAAGSGTPREEEGPAGEAAASQPQAPTSVPGARLSRLPLARVKALVKADPDVTLAG
QEAIFILARAAELFVETIAKDAYCCAQQGKRKTLQRRDLDNAIEAVDEFAFLEGTLD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017159|DNA polymerase epsilon subunit 4 (POLE4)
ATGGCGGCGGCGGCGGCGGCAGGAAGCGGGACGCCCCGAGAGGAGGAGGGACCTGCTGGG
GAGGCAGCGGCCTCGCAGCCCCAGGCCCCAACGAGTGTGCCTGGGGCTCGTCTCTCGAGG
TTGCCTCTGGCGCGAGTGAAGGCCTTGGTGAAGGCAGATCCCGACGTGACGCTAGCGGGA
CAGGAAGCCATCTTCATTCTGGCACGAGCCGCGGAACTGTTTGTGGAGACCATTGCAAAA
GATGCCTACTGTTGCGCTCAGCAGGGAAAAAGGAAAACCCTTCAGAGGAGAGACTTGGAT
AATGCAATAGAAGCTGTGGATGAATTTGCTTTTCTGGAAGGTACTTTAGATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00808</identifier>
            <name>CBFD_NFYB_HMF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>Ada2/Gcn5/Ada3 transcription activator complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>epsilon DNA polymerase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA-directed DNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>histone H3 acetylation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0000250</id>
      <name>Purine nucleoside phosphorylase</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4386</ref-id>
            <pubmed-id>8521855</pubmed-id>
            <citation>Bzowska A, Kazimierczuk Z: 2-Chloro-2'-deoxyadenosine (cladribine) and its analogues are good substrates and potent selective inhibitors of Escherichia coli purine-nucleoside phosphorylase. Eur J Biochem. 1995 Nov 1;233(3):886-90.</citation>
          </article>
          <article>
            <ref-id>A4387</ref-id>
            <pubmed-id>10444166</pubmed-id>
            <citation>Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, MacKey J: Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999 Jul;106(1):78-85.</citation>
          </article>
          <article>
            <ref-id>A4388</ref-id>
            <pubmed-id>10500836</pubmed-id>
            <citation>Dumontet C, Bauchu EC, Fabianowska K, Lepoivre M, Wyczechowska D, Bodin F, Rolland MO: Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562. Adv Exp Med Biol. 1999;457:571-7.</citation>
          </article>
          <article>
            <ref-id>A4389</ref-id>
            <pubmed-id>3260648</pubmed-id>
            <citation>Takimoto T, Kubota M, Tsuruta S, Kitoh T, Tanizawa A, Akiyama Y, Kiriyama Y, Mikawa H: Changes in sensitivity to anticancer drugs during TPA-induced cellular differentiation in a human T-lymphoblastoid cell line (MOLT-4). Leukemia. 1988 Jul;2(7):443-6.</citation>
          </article>
          <article>
            <ref-id>A4390</ref-id>
            <pubmed-id>6808516</pubmed-id>
            <citation>Carson DA, Wasson DB, Lakow E, Kamatani N: Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc Natl Acad Sci U S A. 1982 Jun;79(12):3848-52.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00491" source="Swiss-Prot">
        <name>Purine nucleoside phosphorylase</name>
        <general-function>Purine-nucleoside phosphorylase activity</general-function>
        <specific-function>The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate.</specific-function>
        <gene-name>PNP</gene-name>
        <locus>14q13.1</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.95</theoretical-pi>
        <molecular-weight>32117.69</molecular-weight>
        <chromosome-location>14</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7892</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NP</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X00737</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35565</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2841</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P00491</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PNPH_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.2.1</synonym>
          <synonym>Inosine phosphorylase</synonym>
          <synonym>Inosine-guanosine phosphorylase</synonym>
          <synonym>NP</synonym>
          <synonym>PNP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010033|Purine nucleoside phosphorylase
MENGYTYEDYKNTAEWLLSHTKHRPQVAIICGSGLGGLTDKLTQAQIFDYGEIPNFPRST
VPGHAGRLVFGFLNGRACVMMQGRFHMYEGYPLWKVTFPVRVFHLLGVDTLVVTNAAGGL
NPKFEVGDIMLIRDHINLPGFSGQNPLRGPNDERFGDRFPAMSDAYDRTMRQRALSTWKQ
MGEQRELQEGTYVMVAGPSFETVAECRVLQKLGADAVGMSTVPEVIVARHCGLRVFGFSL
ITNKVIMDYESLEKANHEEVLAAGKQAAQKLEQFVSILMASIPLPDKAS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010034|Purine nucleoside phosphorylase (PNP)
ATGGAGAACGGATACACCTATGAAGATTATAAGAACACTGCAGAATGGCTTCTGTCTCAC
ACTAAGCACCGACCTCAAGTTGCAATAATCTGTGGTTCTGGATTAGGAGGTCTGACTGAT
AAATTAACTCAGGCCCAGATCTTTGACTACGGTGAAATCCCCAACTTTCCCCGAAGTACA
GTGCCAGGTCATGCTGGCCGACTGGTGTTTGGGTTCCTGAATGGCAGGGCCTGTGTGATG
ATGCAGGGCAGGTTCCACATGTATGAAGGGTACCCACTCTGGAAGGTGACATTCCCAGTG
AGGGTTTTCCACCTTCTGGGTGTGGACACCCTGGTAGTCACCAATGCAGCAGGAGGGCTG
AACCCCAAGTTTGAGGTTGGAGATATCATGCTGATCCGTGACCATATCAACCTACCTGGT
TTCAGTGGTCAGAACCCTCTCAGAGGGCCCAATGATGAAAGGTTTGGAGATCGTTTCCCT
GCCATGTCTGATGCCTACGACCGGACTATGAGGCAGAGGGCTCTCAGTACCTGGAAACAA
ATGGGGGAGCAACGTGAGCTACAGGAAGGCACCTATGTGATGGTGGCAGGCCCCAGCTTT
GAGACTGTGGCAGAATGTCGTGTGCTGCAGAAGCTGGGAGCAGACGCTGTTGGCATGAGT
ACAGTACCAGAAGTTATCGTTGCACGGCACTGTGGACTTCGAGTCTTTGGCTTCTCACTC
ATCACTAACAAGGTCATCATGGATTATGAAAGCCTGGAGAAGGCCAACCATGAAGAAGTC
TTAGCAGCTGGCAAACAAGCTGCACAGAAATTGGAACAGTTTGTCTCCATTCTTATGGCC
AGCATTCCACTCCCTGACAAAGCCAGTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01048</identifier>
            <name>PNP_UDP_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleoside binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphate ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>purine nucleobase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>purine-nucleoside phosphorylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inosine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interleukin-2 secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>NAD biosynthesis via nicotinamide riboside salvage pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nicotinamide riboside catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of alpha-beta T cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleotide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine-containing compound salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme>
      <id>BE0002804</id>
      <name>Deoxycytidine kinase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A349</ref-id>
            <pubmed-id>20689698</pubmed-id>
            <citation>Warnke C, Wiendl H, Hartung HP, Stuve O, Kieseier BC: Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther. 2010 Jul 21;4:117-26.</citation>
          </article>
          <article>
            <ref-id>A350</ref-id>
            <pubmed-id>20634380</pubmed-id>
            <citation>Sigal DS, Miller HJ, Schram ED, Saven A: Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010 Oct 21;116(16):2884-96. doi: 10.1182/blood-2010-02-246140. Epub 2010  Jul 15.</citation>
          </article>
          <article>
            <ref-id>A353</ref-id>
            <pubmed-id>17852710</pubmed-id>
            <citation>Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.</citation>
          </article>
          <article>
            <ref-id>A352</ref-id>
            <pubmed-id>19715446</pubmed-id>
            <citation>Sampat K, Kantarjian H, Borthakur G: Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.</citation>
          </article>
          <article>
            <ref-id>A354</ref-id>
            <pubmed-id>19576186</pubmed-id>
            <citation>Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1.</citation>
          </article>
          <article>
            <ref-id>A355</ref-id>
            <pubmed-id>19463072</pubmed-id>
            <citation>Larson ML, Venugopal P: Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jun;10(8):1353-7. doi: 10.1517/14656560902997990.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P27707" source="Swiss-Prot">
        <name>Deoxycytidine kinase</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.</specific-function>
        <gene-name>DCK</gene-name>
        <locus>4q13.3-q21.1</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.88</theoretical-pi>
        <molecular-weight>30518.315</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2704</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DCK</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M60527</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P27707</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DCK_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.1.74</synonym>
          <synonym>dCK</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016896|Deoxycytidine kinase
MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEVVPEPVARWCN
VQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAE
KPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQA
TPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNE
DFKDKYESLVEKVKEFLSTL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016897|Deoxycytidine kinase (DCK)
ATGGCCACCCCGCCCAAGAGAAGCTGCCCGTCTTTCTCAGCCAGCTCTGAGGGGACCCGC
ATCAAGAAAATCTCCATCGAAGGGAACATCGCTGCAGGGAAGTCAACATTTGTGAATATC
CTTAAACAATTGTGTGAAGATTGGGAAGTGGTTCCTGAACCTGTTGCCAGATGGTGCAAT
GTTCAAAGTACTCAAGATGAATTTGAGGAACTTACAATGTCTCAGAAAAATGGTGGGAAT
GTTCTTCAGATGATGTATGAGAAACCTGAACGATGGTCTTTTACCTTCCAAACATATGCC
TGTCTCAGTCGAATAAGAGCTCAGCTTGCCTCTCTGAATGGCAAGCTCAAAGATGCAGAG
AAACCTGTATTATTTTTTGAACGATCTGTGTATAGTGACAGGTATATTTTTGCATCTAAT
TTGTATGAATCTGAATGCATGAATGAGACAGAGTGGACAATTTATCAAGACTGGCATGAC
TGGATGAATAACCAATTTGGCCAAAGCCTTGAATTGGATGGAATCATTTATCTTCAAGCC
ACTCCAGAGACATGCTTACATAGAATATATTTACGGGGAAGAAATGAAGAGCAAGGCATT
CCTCTTGAATATTTAGAGAAGCTTCATTATAAACATGAAAGCTGGCTCCTGCATAGGACA
CTGAAAACCAACTTCGATTATCTTCAAGAGGTGCCTATCTTAACACTGGATGTTAATGAA
GACTTTAAAGACAAATATGAAAGTCTGGTTGAAAAGGTCAAAGAGTTTTTGAGTACTTTG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01712</identifier>
            <name>dNK</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>deoxycytidine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleoside kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleoside monophosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine-containing compound salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleotide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="11">
      <id>BE0001067</id>
      <name>ATP-binding cassette sub-family G member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16483</ref-id>
            <pubmed-id>18765824</pubmed-id>
            <citation>de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, Beijnen J, Borst P: Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. doi: 10.1158/1535-7163.MCT-08-0427. Epub 2008 Sep 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UNQ0" source="Swiss-Prot">
        <name>ATP-binding cassette sub-family G member 2</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.</specific-function>
        <gene-name>ABCG2</gene-name>
        <locus>4q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>396-416
429-449
478-498
507-527
536-556
631-651</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.9</theoretical-pi>
        <molecular-weight>72313.47</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:74</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF103796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4185796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UNQ0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABCP</synonym>
          <synonym>BCRP</synonym>
          <synonym>BCRP1</synonym>
          <synonym>Breast cancer resistance protein</synonym>
          <synonym>CDw338</synonym>
          <synonym>Mitoxantrone resistance-associated protein</synonym>
          <synonym>MXR</synonym>
          <synonym>Placenta-specific ATP-binding cassette transporter</synonym>
          <synonym>Urate exporter</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002125|ATP-binding cassette sub-family G member 2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT
GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA
ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA
ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF01061</identifier>
            <name>ABC2_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="12">
      <id>BE0003672</id>
      <name>Solute carrier family 28 member 3</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A17898</ref-id>
            <pubmed-id>15738947</pubmed-id>
            <citation>Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM: Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005;5(3):157-65.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9HAS3" source="Swiss-Prot">
        <name>Solute carrier family 28 member 3</name>
        <general-function>Pyrimidine- and adenine-specific:sodium symporter activity</general-function>
        <specific-function>Sodium-dependent, pyrimidine- and purine-selective. Involved in the homeostasis of endogenous nucleosides. Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtype (N3/cib) (with marked transport of both thymidine and inosine). Employs a 2:1 sodium/nucleoside ratio. Also able to transport gemcitabine, 3'-azido-3'-deoxythymidine (AZT), ribavirin and 3-deazauridine.</specific-function>
        <gene-name>SLC28A3</gene-name>
        <locus>9q22.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>103-123
128-148
171-191
201-221
224-244
288-308
315-335
362-382
389-409
444-464
480-500
554-574
594-614</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.67</theoretical-pi>
        <molecular-weight>76929.61</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:16484</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF305210</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>10732815</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1116</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9HAS3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S28A3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CNT 3</synonym>
          <synonym>CNT3</synonym>
          <synonym>Concentrative Na(+)-nucleoside cotransporter 3</synonym>
          <synonym>hCNT3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007057|Solute carrier family 28 member 3
MELRSTAAPRAEGYSNVGFQNEENFLENENTSGNNSIRSRAVQSREHTNTKQDEEQVTVE
QDSPRNREHMEDDDEEMQQKGCLERRYDTVCGFCRKHKTTLRHIIWGILLAGYLVMVISA
CVLNFHRALPLFVITVAAIFFVVWDHLMAKYEHRIDEMLSPGRRLLNSHWFWLKWVIWSS
LVLAVIFWLAFDTAKLGQQQLVSFGGLIMYIVLLFLFSKYPTRVYWRPVLWGIGLQFLLG
LLILRTDPGFIAFDWLGRQVQTFLEYTDAGASFVFGEKYKDHFFAFKVLPIVVFFSTVMS
MLYYLGLMQWIIRKVGWIMLVTTGSSPIESVVASGNIFVGQTESPLLVRPYLPYITKSEL
HAIMTAGFSTIAGSVLGAYISFGVPSSHLLTASVMSAPASLAAAKLFWPETEKPKITLKN
AMKMESGDSGNLLEAATQGASSSISLVANIAVNLIAFLALLSFMNSALSWFGNMFDYPQL
SFELICSYIFMPFSFMMGVEWQDSFMVARLIGYKTFFNEFVAYEHLSKWIHLRKEGGPKF
VNGVQQYISIRSEIIATYALCGFANIGSLGIVIGGLTSMAPSRKRDIASGAVRALIAGTV
ACFMTACIAGILSSTPVDINCHHVLENAFNSTFPGNTTKVIACCQSLLSSTVAKGPGEVI
PGGNHSLYSLKGCCTLLNPSTFNCNGISNTF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020702|Solute carrier family 28 member 3 (SLC28A3)
ATGGAGCTGAGGAGTACAGCAGCCCCCAGAGCTGAGGGCTACAGCAACGTGGGCTTCCAG
AATGAAGAAAACTTTCTTGAGAACGAGAACACATCAGGAAACAACTCAATAAGAAGCAGA
GCTGTGCAAAGCAGGGAGCACACAAACACCAAACAGGATGAAGAACAGGTCACAGTTGAG
CAGGATTCTCCAAGAAACAGAGAACACATGGAGGATGATGATGAGGAGATGCAACAAAAA
GGGTGTTTGGAAAGGAGGTATGACACAGTATGTGGTTTCTGTAGGAAACACAAAACAACT
CTTCGGCACATCATCTGGGGCATTTTATTAGCAGGTTATCTGGTTATGGTGATTTCGGCC
TGTGTGCTGAACTTTCACAGAGCCCTTCCTCTTTTTGTGATCACCGTGGCTGCCATCTTC
TTTGTTGTCTGGGATCACCTGATGGCCAAATACGAACATCGAATTGATGAGATGCTGTCT
CCTGGCAGAAGGCTTCTAAACAGCCATTGGTTCTGGCTGAAGTGGGTGATCTGGAGCTCC
CTGGTCCTAGCAGTTATTTTCTGGTTGGCCTTTGACACTGCCAAATTGGGTCAACAGCAG
CTGGTGTCCTTCGGTGGGCTCATAATGTACATTGTCCTGTTATTTCTATTTTCCAAGTAC
CCAACCAGAGTTTACTGGAGACCTGTCTTATGGGGAATCGGGCTACAGTTTCTTCTTGGG
CTCTTGATTCTAAGGACTGACCCTGGATTTATAGCTTTTGATTGGTTGGGCAGACAAGTT
CAGACTTTTCTGGAGTACACAGATGCTGGTGCTTCATTTGTCTTTGGTGAGAAATACAAA
GACCACTTCTTTGCATTTAAGGTCCTGCCGATCGTGGTTTTCTTCAGCACTGTGATGTCC
ATGCTGTACTACCTGGGACTGATGCAGTGGATTATTAGAAAGGTTGGATGGATCATGCTA
GTTACTACGGGATCATCTCCTATTGAATCTGTAGTTGCTTCTGGCAATATATTTGTTGGA
CAAACGGAGTCTCCACTGCTGGTCCGACCATATTTACCTTACATCACCAAGTCTGAACTC
CACGCCATCATGACCGCCGGGTTCTCTACCATTGCTGGAAGCGTGCTAGGTGCATACATT
TCTTTTGGGGTTCCATCCTCCCACTTGTTAACAGCGTCAGTTATGTCAGCACCTGCGTCA
TTGGCTGCTGCTAAACTCTTTTGGCCTGAGACAGAAAAACCTAAAATAACCCTCAAGAAT
GCCATGAAAATGGAAAGTGGTGATTCAGGGAATCTTCTAGAAGCTGCAACACAGGGAGCA
TCCTCCTCCATCTCCCTGGTGGCCAACATCGCTGTGAATCTGATTGCCTTCCTGGCCCTG
CTGTCTTTTATGAATTCAGCCCTGTCCTGGTTTGGAAACATGTTTGACTACCCACAGCTG
AGTTTTGAGCTAATCTGCTCCTACATCTTCATGCCCTTTTCCTTCATGATGGGAGTGGAA
TGGCAGGACAGCTTTATGGTTGCCAGACTCATAGGTTATAAGACCTTCTTCAATGAATTT
GTGGCTTATGAGCACCTCTCAAAATGGATCCACTTGAGGAAAGAAGGTGGACCCAAATTT
GTAAACGGTGTGCAGCAATATATATCAATTCGTTCTGAGATAATCGCCACTTACGCTCTC
TGTGGTTTTGCCAATATCGGGTCCCTAGGAATCGTGATCGGCGGACTCACATCCATGGCT
CCTTCCAGAAAGCGTGATATCGCCTCGGGGGCAGTGAGAGCTCTGATTGCGGGGACCGTG
GCCTGCTTCATGACAGCCTGCATCGCAGGCATACTCTCCAGCACTCCTGTGGACATCAAC
TGCCATCACGTTTTAGAGAATGCCTTCAACTCCACTTTCCCTGGAAACACAACCAAGGTG
ATAGCTTGTTGCCAAAGTCTGTTGAGCAGCACTGTTGCCAAGGGTCCTGGTGAAGTCATC
CCAGGAGGAAACCACAGTCTGTATTCTTTGAAGGGCTGCTGCACATTGTTGAATCCATCG
ACCTTTAACTGCAATGGGATCTCTAATACATTTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07670</identifier>
            <name>Gate</name>
          </pfam>
          <pfam>
            <identifier>PF07662</identifier>
            <name>Nucleos_tra2_C</name>
          </pfam>
          <pfam>
            <identifier>PF01773</identifier>
            <name>Nucleos_tra2_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>purine-specific nucleoside</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyrimidine- and adenine-specific</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleoside transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine-containing compound transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>